Document:

EX-10.15

 Exhibit 10.15 

LIMITED LIABILITY COMPANY AGREEMENT 

OF 
 V2ACT THERAPEUTICS,
LLC 
 The Interests referred to in this Limited Liability Company Agreement have not been registered under the Securities Act of 1933 or any other
securities laws, and such Interests may not be transferred without appropriate registration or the availability of an exemption from such registration requirements. 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
	 ARTICLE I—DEFINITIONS
	  	 	1	 
		 	 1.1
	 	Terms Defined Herein	  	 	1	 
		 	 1.2
	 	Certain Interpretive Matters	  	 	4	 
		
	 ARTICLE II—BUSINESS PURPOSES AND OFFICES
	  	 	6	 
				
		 	 2.1
	 	Name; Business Purpose	  	 	6	 
		 	 2.2
	 	Powers	  	 	6	 
		 	 2.3
	 	Principal Office	  	 	6	 
		 	 2.4
	 	Registered Office and Registered Agent	  	 	6	 
		 	 2.5
	 	Amendment of the Certificate	  	 	6	 
		 	 2.6
	 	Effective Date	  	 	6	 
		 	 2.7
	 	Liability of Members and Manager	  	 	6	 
		 	 2.8
	 	Interest Not Acquired for Resale	  	 	6	 
		
	 ARTICLE III—CAPITAL CONTRIBUTIONS AND LOANS
	  	 	7	 
				
		 	 3.1
	 	Capital Contributions	  	 	7	 
		 	 3.2
	 	Additional Capital Contributions	  	 	7	 
		 	 3.3
	 	Capital Accounts	  	 	7	 
		 	 3.4
	 	Capital Withdrawal Rights, Interest and Priority	  	 	8	 
		 	 3.5
	 	Loans	  	 	8	 
		
	 ARTICLE IV—ALLOCATIONS AND DISTRIBUTIONS
	  	 	8	 
				
		 	 4.1
	 	Non-Liquidation Cash Distributions	  	 	8	 
		 	 4.2
	 	Liquidation Distributions	  	 	8	 
		 	 4.3
	 	Income, Losses and Distributive Shares of Tax Items	  	 	9	 
		 	 4.4
	 	Allocation of Income, Loss and Credits	  	 	9	 
		 	 4.5
	 	Special Rules Regarding Allocation of Tax Items	  	 	10	 
		 	 4.6
	 	Withholding of Distributions	  	 	12	 
		 	 4.7
	 	No Priority	  	 	12	 
		 	 4.8
	 	Tax Withholding	  	 	12	 
		 	 4.9
	 	Reserves	  	 	13	 
		
	 ARTICLE V—MANAGEMENT
	  	 	13	 
				
		 	 5.1
	 	Management	  	 	13	 
		 	 5.2
	 	Election of the Management Committee	  	 	13	 
		 	 5.3
	 	Meetings of the Management Committee; Place of Meetings	  	 	13	 
		 	 5.4
	 	Quorum; Voting Requirement	  	 	13	 
		 	 5.5
	 	Notice of Meeting	  	 	14	 
		 	 5.6
	 	Waiver of Notice	  	 	14	 
		 	 5.7
	 	Action Without a Meeting	  	 	14	 
		 	 5.8
	 	Compensation of Managers	  	 	14	 
		 	 5.9
	 	Restrictions on Authority of Management Committee	  	 	14	 
		 	 5.10
	 	Meetings of Members; Place of Meetings	  	 	14	 
		 	 5.11
	 	Quorum; Voting Requirement	  	 	15	 
		 	 5.12
	 	Proxies	  	 	15	 

  
 i 

 TABLE OF CONTENTS 

(Continued) 
  

									
	 	 	 	 	 	  	Page	 
	     
	 	 5.13
	 	Action Without Meeting	  	 	15	 
		 	 5.14
	 	Notice of Meetings	  	 	15	 
		 	 5.15
	 	Waiver of Notice	  	 	15	 
		 	 5.16
	 	Documents Filed with Delaware Secretary of State	  	 	16	 
		 	 5.17
	 	Voting by Certain Holders	  	 	16	 
		 	 5.18
	 	Limitation of Liability; Indemnification.	  	 	16	 
		 	 5.19
	 	Contracts with Members, Managers, or Their Affiliates	  	 	19	 
		 	 5.20
	 	Other Business Ventures	  	 	19	 
		
	 ARTICLE VI—ACCOUNTING AND BANK ACCOUNTS
	  	 	20	 
				
		 	 6.1
	 	Fiscal Year	  	 	20	 
		 	 6.2
	 	Books and Records	  	 	20	 
		 	 6.3
	 	Financial Reports	  	 	20	 
		 	 6.4
	 	Tax Returns and Elections; Tax Matters Representative	  	 	20	 
		 	 6.5
	 	Section 754 Election	  	 	21	 
		 	 6.6
	 	Bank Accounts	  	 	21	 
		
	 ARTICLE VII—TRANSFERS OF INTERESTS AND EVENTS OF WITHDRAWAL
	  	 	22	 
				
		 	 7.1
	 	General Restrictions	  	 	22	 
		 	 7.2
	 	Permitted Transfers	  	 	22	 
		 	 7.3
	 	Substitute Members	  	 	22	 
		 	 7.4
	 	Effect of Admission as a Substitute Member	  	 	22	 
		 	 7.5
	 	Additional Members and Interests	  	 	23	 
		 	 7.6
	 	Redemption of Interests	  	 	23	 
		 	 7.7
	 	Events of Withdrawal	  	 	23	 
		
	 ARTICLE VIII—DISSOLUTION AND TERMINATION
	  	 	25	 
				
		 	 8.1
	 	Events Causing Dissolution	  	 	25	 
		 	 8.2
	 	Effect of Dissolution	  	 	25	 
		 	 8.3
	 	Application of Proceeds	  	 	25	 
		
	 ARTICLE IX—MISCELLANEOUS
	  	 	25	 
				
		 	 9.1
	 	Title to the Property	  	 	25	 
		 	 9.2
	 	Nature of Interest in the Company	  	 	25	 
		 	 9.3
	 	Organizational Expenses	  	 	26	 
		 	 9.4
	 	Notices	  	 	26	 
		 	 9.5
	 	Waiver of Default	  	 	26	 
		 	 9.6
	 	No Third Party Rights	  	 	26	 
		 	 9.7
	 	Entire Agreement	  	 	26	 
		 	 9.8
	 	Amendments to this Agreement.	  	 	26	 
		 	 9.9
	 	Severability	  	 	27	 
		 	 9.10
	 	Binding Agreement	  	 	27	 
		 	 9.11
	 	Counterparts	  	 	27	 
		 	 9.12
	 	Governing Law	  	 	27	 
		 	 9.13
	 	Remedies	  	 	27	 
		 	 9.14
	 	Legal Representation	  	 	28	 

  
 ii 

 TABLE OF CONTENTS 

(Continued) 
  

							
	 	 	 	  	Page	 
	SCHEDULE A	  			

  
 iii 

 LIMITED LIABILITY COMPANY AGREEMENT 

OF 
 V2ACT THERAPEUTICS,
LLC 
 This Limited Liability Company Agreement (this “Agreement”) of V2ACT Therapeutics, LLC, a Delaware limited
liability company (the “Company”), is entered into as of January 3, 2019, by and among the Company, TVAX Biomedical, Inc., a Delaware corporation (“TVAX”), and Genelux Corporation, a Delaware corporation
(“Genelux”). 
 The Company was formed as a limited liability company under the Delaware Limited Liability Company Act and,
as required thereunder, the parties hereto hereby adopt this Agreement as the limited liability company agreement of the Company. 
 The
parties hereto agree as follows: 
 ARTICLE I—DEFINITIONS 

1.1 Terms Defined Herein. As used herein, the following terms have the following meanings: 

“Act” means the Delaware Limited Liability Company Act. 

“Adjusted Capital Account Deficit” means, with respect to any Member, the deficit balance, if any, in such Member’s
Capital Account as of the end of the relevant fiscal year, after giving effect to the following adjustments: (i) increased for any amounts such is unconditionally obligated to restore and the amount of such Member’s share of Company
Minimum Gain and Member Minimum Gain after taking into account any changes during such year; and (ii) reduced by the items described in Treasury Regulation § 1.704-1(b)(2)(ii)(d)(4), (5) and
(6). 
 “Agreement” means the Limited Liability Company Agreement of the Company. 

“Available Cash” means the aggregate amount of cash on hand or in bank, money market or similar accounts of the
Company as of the end of each fiscal quarter, or other applicable period, derived from any source (other than Capital Contributions and Liquidation Proceeds) that the Management Committee determines is available for distribution to the Members after
taking into account any amount required or appropriate to maintain a reasonable amount of Reserves. 
 “Bankruptcy”, with
respect to any Person, means the entry of an order for relief with respect to such Person under the Federal Bankruptcy Code or the insolvency of such Person under any state insolvency act. 

“Capital Account” means the separate account established and maintained by the Company for each Member and each
Transferee pursuant to Section 3.3. 
 “Capital Contribution” means with respect to a Member the total amount
of cash and the agreed upon net Fair Value of property contributed by such Member (or such Member’s predecessor in interest) to the capital of the Company for such Member’s Interest. 

 “Certificate” means the Certificate of Formation of the Company
filed with the Delaware Secretary of State. 
 “Code” means the Internal Revenue Code of 1986. 

“Company” means V2ACT Therapeutics, LLC, a Delaware limited liability company. 

“Company Minimum Gain” has the same meaning as partnership minimum gain set forth in Treasury Regulation § 1.704-2(d)(1). Company Minimum Gain is determined, first, by computing for each Nonrecourse Debt any gain that the Company would realize if the Company disposed of the property subject to that liability
for no consideration other than full satisfaction of such liability and, then, aggregating the separately computed gains. For purposes of computing gain, the Company will use the basis of such property that is used for purposes of determining the
amount of the Capital Accounts under Section 3.3. In any taxable year in which a Revaluation occurs, the net increase or decrease in Company Minimum Gain for such taxable year will be determined by: (1) calculating the net decrease or
increase in Company Minimum Gain using the current year’s book value and the prior year’s amount of Company Minimum Gain; and (2) adding back any decrease in Company Minimum Gain arising solely from the Revaluation. 

“Credits” means all tax credits allowed by the Code with respect to activities of the Company or the Property. 

“Distributions” means any distributions by the Company to the Members of Available Cash or Liquidation Proceeds or other
amounts. 
 “Event of Withdrawal” means an event upon the occurrence of which a Member ceases to be a Member of the Company
pursuant to Section 7.7. 
 “Fair Value” of an asset means its fair market value. 

“Income” and “Loss” mean, respectively, for each fiscal year or other period, an amount equal to the
Company’s taxable income or loss for such year or period, determined in accordance with Code § 703(a), except that for this purpose: (i) all items of income, gain, deduction or loss required to be separately stated by Code
§ 703(a)(1) will be included in taxable income or loss; (ii) tax exempt income will be added to taxable income or loss; (iii) any expenditures described in Code § 705(a)(2)(B) (or treated as Code
§ 705(a)(2)(B) expenditures pursuant to Treasury Regulation § 1.704-1(b)(2)(iv)(i)) and not otherwise taken into account in computing taxable income or loss will be subtracted; and
(iv) taxable income or loss will be adjusted to reflect any item of income or loss specifically allocated in Article IV. 

“Initial Capital Contributions” means the Capital Contributions made by the Members pursuant to Section 3.1. 

“Interest” refers to all of a Member’s rights and interests in the Company in such Member’s capacity as a Member,
all as provided in the Certificate, this Agreement and the Act, including the Member’s interest in the capital, income, gain, deductions, losses, and credits of the Company. 

  
 2 

 “Liquidation Proceeds” means all Property at the time of liquidation of the
Company and all proceeds thereof. 
 “Majority in Interest” means any Member or group of Members holding an aggregate of
more than 50% of the Percentage Interests held by all Members. 
 “Management Committee” means the group of Managers
elected by the Members pursuant to Article V to manage the business and affairs of the Company. 
 “Manager” means each of
the natural persons elected by the Members pursuant to Article V to serve on the Management Committee. 
 “Member” means
each Person executing this Agreement and each Person who is subsequently admitted to the Company as a Member pursuant to Section 7.3 or Section 7.5, other than a Person who ceases to be a Member of the Company pursuant to Section 7.7
as a result of an Event of Withdrawal. 
 “Member Minimum Gain” has the same meaning as partner nonrecourse debt minimum
gain as set forth in Treasury Regulation § 1.704-2(i)(3). With respect to each Member Nonrecourse Debt, Member Minimum Gain will be determined by computing for each Member Nonrecourse Debt any gain
that the Company would realize if the Company disposed of the property subject to that liability for no consideration other than full satisfaction of such liability. For purposes of computing gain, the Company will use the basis of such property
that is used for purposes of determining the amount of the Capital Accounts under Section 3.3. In any taxable year in which a Revaluation occurs, the net increase or decrease in Member Minimum Gain for such taxable year will be determined by:
(1) calculating the net decrease or increase in Member Minimum Gain using the current year’s book value and the prior year’s amount of Member Minimum Gain; and (2) adding back any decrease in Member Minimum Gain arising solely
from the Revaluation. 
 “Member Nonrecourse Debt” has the same meaning as partner nonrecourse debt set forth in Treasury
Regulation § 1.704-2(b)(4). 
 “Member Nonrecourse Deductions” has the
same meaning as partner nonrecourse deductions set forth in Treasury Regulation § 1.704-2(i)(2). Generally, the amount of Member Nonrecourse Deductions with respect to a Member Nonrecourse Debt for a
fiscal year equals the net increase during the year in the amount of the Member Minimum Gain (determined in accordance with Treasury Regulation § 1.704-2(i)) reduced (but not below zero) by the
aggregate distributions made during the year of proceeds of Member Nonrecourse Debt and allocable to the increase in Member Minimum Gain determined according to the provisions of Treasury Regulation
§ 1.704-2(i). 
 “Nonrecourse Debt” means a Company liability with
respect to which no Member bears the economic risk of loss as determined under Treasury Regulation §§ 1.752-1(a)(2) and 1.752-2. 

  
 3 

 “Nonrecourse Deductions” has the same meaning as nonrecourse deductions set
forth in Treasury Regulation § 1.704-2(c). Generally, the amount of Nonrecourse Deductions for a fiscal year equals the net increase in the amount of Company Minimum Gain (determined in accordance
with Treasury Regulation § 1.704.2(d)) during such year reduced (but not below zero) by the aggregate distributions made during the year of proceeds of a Nonrecourse Debt that are allocable to the increase in Company Minimum Gain,
determined according to the provisions of Treasury Regulation § 1.704-2(c) and (h). 

“Percentage Interest”, of each Member, will be as set forth on Schedule A, as adjusted from time to time as required
or permitted by the provisions of this Agreement. 
 “Person” means any individual, partnership, limited liability company,
corporation, cooperative, trust or other entity. 
 “Presiding Manager” has the meaning set forth in Section 5.1. 

“Prime Rate” means the annual rate of interest reported from time to time in The Wall Street Journal as the base rate
on corporate loans at large money center commercial banks. 
 “Property” means all properties and assets that the Company
may own or otherwise have an interest in from time to time. 
 “Reserves” means amounts set aside from time to time by the
Management Committee pursuant to Section 4.9. 
 “Revaluation” means the occurrence of any event described in clause
(x), (y) or (z) of Section 3.3 in which the book basis of Property is adjusted to its Fair Value. 
 “Substitute
Member” has the meaning set forth in Section 7.3. 
 “Super-Majority in Interest” means any Member or group
of Members holding an aggregate of more than 60% of the Percentage Interests held by all Members. 
 “Tax Matters Member”
means the Person designated pursuant to Section 6.4 to represent the Company in matters before the Internal Revenue Service. 

“Transfer” means (i) when used as a verb, to give, sell, exchange, assign, transfer, pledge, hypothecate, bequeath,
devise or otherwise dispose of or encumber, and (ii) when used as a noun, the nouns corresponding to such verbs, in either case voluntarily or involuntarily, by operation of law or otherwise. 

“Transferee” has the meaning set forth in Section 7.2. 

“Transferor” has the meaning set forth in Section 7.2. 

“Treasury Regulations” means the regulations promulgated by the Treasury Department with respect to the Code. 

1.2 Certain Interpretive Matters. In construing this Agreement, it is the intent of the parties that: 

  
 4 

 (a) the captions of the articles, sections or subsections, or to the
Table of Contents in this Agreement are inserted for convenience in locating the provisions of this Agreement and not as an aid in its construction; 

(b) no consideration may be given to the fact or presumption that one party had a greater or lesser hand in drafting
this Agreement; 
 (c) examples are not to be construed to limit, expressly or by implication, the matter they
illustrate; 
 (d) the word “includes” and its derivatives means “includes, but is not limited
to,” and corresponding derivative expressions; 
 (e) a defined term has its defined meaning throughout this
Agreement and each exhibit and schedule to this Agreement, regardless of whether it appears before or after the place where it is defined; 

(f) the meanings of the defined terms are applicable to both the singular and plural forms thereof; 

(g) all references to prices, values or monetary amounts refer to United States dollars; 

(h) all references to articles, sections, paragraphs, clauses, exhibits or schedules refer to articles, sections,
paragraphs and clauses of this Agreement, and to exhibits or schedules attached to this Agreement, unless expressly provided otherwise; 

(i) each exhibit and schedule to this Agreement is a part of this Agreement and references to the term
“Agreement” are deemed to include each such exhibit and schedule to this Agreement except to the extent that the context indicates otherwise, but if there is any conflict or inconsistency between the body of this Agreement and any exhibit
or schedule, the provisions of the body of this Agreement will control; 
 (j) the words “this Agreement,”
“herein,” “hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular article, section or other subdivision, unless expressly so limited; 

(k) the word “or” is disjunctive but not necessarily exclusive; 

(l) all references to agreements or laws are deemed to refer to such agreements or laws as amended or revised or as in
effect at the applicable time, including corresponding provisions of future agreements or laws; and 
 (m) as used in
this Agreement, accounting terms not defined in this Agreement, and accounting terms partly defined to the extent not defined, will have the respective meanings given to them under United States generally accepted accounting principles. 

  
 5 

 ARTICLE II—BUSINESS PURPOSES AND OFFICES 

2.1 Name; Business Purpose. The name of the Company is stated in the Certificate. The business purpose of the Company is
to engage in the development of the Company’s technology, which is a combination of TVAX’s immunotherapy and Genelux’s Oncolytic vaccinia virotherapy, and to do any and all things necessary, appropriate, or incidental thereto. The
Company is formed only for such business purpose and will not be deemed to create any agreement among the Members with respect to any other activities whatsoever other than the activities within such business purpose. 

2.2 Powers. In addition to the powers and privileges conferred upon the Company by law and those incidental thereto, the
Company has the same powers as a natural person to do all things necessary or convenient to carry out its business and affairs. 

2.3 Principal Office. The principal office of the Company will be located at 10900 S. Clay Blair Boulevard, Suite 700,
Olathe, Kansas 66061 or at such other place as the Management Committee may determine from time to time. 
 2.4 Registered Office
and Registered Agent. The location of the registered office and the name of the registered agent of the Company in the State of Delaware are stated in the Certificate. The registered office and registered agent of the Company in the State
of Delaware may be changed, from time to time, by the Management Committee. 
 2.5 Amendment of the Certificate. The
Company will amend the Certificate at such time or times and in such manner as may be required by the Act and this Agreement. 
 2.6
Effective Date. This Agreement is effective upon the date that the Certificate is filed with the Secretary of State of Delaware. 

2.7 Liability of Members and Manager. No Member or Manager, solely by reason of being a Member or Manager, or both, will
be liable, under a judgment, decree or order of a court, or in any other manner, for a debt, obligation or liability of the Company, whether arising in contract, tort or otherwise, or for the acts or omissions of any other Member, Manager, agent, or
employee of the Company. The failure of the Company to observe any formalities or requirements relating to the exercise of its powers or management of its business or affairs under this Agreement or the Act will not be grounds for imposing liability
on the Members or Managers for the debts, obligations, or liabilities of the Company. 
 2.8 Interest Not Acquired for
Resale. Each Member hereby represents and warrants to the Company and to each other Member that: (a) in the case of a Member who is not a natural person, the Member is duly organized, validly existing, and in good standing under the
law of its state of organization and that it has the requisite power and authority to execute this Agreement and to perform its obligations hereunder; (b) the Member is acquiring an Interest for such Member’s own account as an investment
and without an intent to distribute such Interest; and (c) the Member acknowledges that the Interests have not been registered under the Securities Act of 1933 or any state securities laws, and such Member’s Interest may not be resold or
transferred by the Member without appropriate registration or the availability of an exemption from such requirements. 

  
 6 

 ARTICLE III—CAPITAL CONTRIBUTIONS AND LOANS 

3.1 Capital Contributions. Upon the execution of this Agreement, each Member will make an initial cash contribution to
the capital of the Company in the amount set forth opposite such Member’s name on Schedule A. 
 3.2 Additional
Capital Contributions. The Management Committee is authorized from time to time to cause the Company to raise additional capital from the Members or from Persons who are not Members (a “Capital Increase”). No
Member will have any preemptive right to make an investment in the Company with respect to a Capital Increase by reason of such Member’s ownership of an Interest in the Company. No Member is obligated to make any additional capital
contributions to the Company and, accordingly, no Member will be liable for damage to the Company or any other Member as a result of the failure of such Member to make any additional capital contributions. 

3.3 Capital Accounts. A separate Capital Account will be maintained for each Member and each Transferee. Each
Member’s Capital Account will be (a) increased by (i) the amount of money contributed by such Member, (ii) the Fair Value of property contributed by such Member (net of liabilities secured by such contributed property that the
Company is considered to assume or take subject to under Code § 752), (iii) allocations to such Member, pursuant to Article IV, of Company income and gain (or items thereof), and (iv) to the extent not already netted out under clause
(b)(ii) below, the amount of any Company liabilities assumed by the Member or which are secured by any property distributed to such Member; and (b) decreased by (i) the amount of money distributed to such Member, (ii) the Fair Value
of property distributed to such Member (net of liabilities secured by such distributed property that such Member is considered to assume or take subject to under Code § 752), (iii) allocations to such Member, pursuant to Article IV, of
Company loss and deductions (or items thereof), and (iv) to the extent not already netted out under clause (a)(ii) above, the amount of any liabilities of the Member assumed by the Company or which are secured by any property contributed by
such Member to the Company. 
 If any Interest is transferred in accordance with the terms of this Agreement, the Transferee will succeed to
the Capital Account of the Transferor to the extent it relates to the transferred interest and the Capital Account of each Transferee will be increased and decreased in the manner set forth above. 

In the event of (x) an additional capital contribution by an existing or an additional Member of more than a de minimis amount
that results in a shift in Percentage Interests, (y) the distribution by the Company to a Member of more than a de minimis amount of property as consideration for an Interest or (z) the liquidation of the Company within the meaning
of Treasury Regulation § 1.704-1(b)(2)(ii)(g), the book basis of the Property will be adjusted to Fair Value and the Capital Accounts of all the Members will be adjusted simultaneously to reflect the
aggregate net adjustment to book basis as if the Company recognized gain or loss equal to the amount of such aggregate net adjustment; provided, however, that the adjustments resulting from clause (x) or (y) above may be made only if the
Members determine that such adjustments are necessary or appropriate to reflect the relative economic interests of the Members. 

  
 7 

 If Property is subject to Code § 704(c) or is revalued on the books of the Company
in accordance with the preceding paragraph pursuant to § 1.704-1(b)(2)(iv)(f) of the Treasury Regulations, the Members’ Capital Accounts will be adjusted in accordance with § 1.704-1(b)(2)(iv)(g) of the Treasury Regulations for allocations to the Members of depreciation, amortization and gain or loss, as computed for book purposes (and not tax purposes) with respect to such
Property. 
 The foregoing provisions of this Section 3.3 and the other provisions of this Agreement relating to the maintenance of
capital accounts are intended to comply with Treasury Regulation §§ 1.704-1(b) and 1.704-2, and must be interpreted and applied in a manner consistent
with such Treasury Regulations. If it is determined by the Members that it is prudent or advisable to modify the manner in which the Capital Accounts, or any increases or decreases thereto, are computed in order to comply with such Treasury
Regulations, the Management Committee may cause such modification to be made provided that it is not likely to have a material effect on the amounts distributable to any Member upon the dissolution of the Company, and the Management Committee, upon
any such determination by the Members, is empowered to amend or modify this Agreement, notwithstanding any other provision of this Agreement. 

3.4 Capital Withdrawal Rights, Interest and Priority. Except as expressly provided in this Agreement, no Member is
entitled to withdraw or reduce such Member’s Capital Account or to receive any Distributions. No Member is entitled to demand or receive any Distribution in any form other than in cash. No Member is entitled to receive or be credited with any
interest on the balance in such Member’s Capital Account at any time. Except as may be otherwise expressly provided herein, no Member has any priority over any other Member as to the return of the balance in such Member’s Capital Account.

 3.5 Loans. Any Member may make a loan to the Company in such amounts, at such times (including in lieu of a capital
contribution under Section 3.2) and on such terms and conditions as may be approved by a Majority in Interest. Loans by any Member to the Company will not be considered contributions to the capital of the Company. 

ARTICLE IV—ALLOCATIONS AND DISTRIBUTIONS 

4.1 Non-Liquidation Cash Distributions. The amount, if any, of Available Cash
will be determined by the Management Committee quarterly and will be distributed to the Members within 45 days following the end of each fiscal quarter in accordance with their respective Percentage Interests. 

4.2 Liquidation Distributions. Liquidation Proceeds will be distributed in the following order of priority: 

(a) To the payment of debts and liabilities of the Company (including to Members to the extent otherwise permitted by
law) and the expenses of liquidation. 
 (b) Next, to the setting up of such reserves as the Person required or
authorized by law to wind up the Company’s affairs may reasonably deem necessary or appropriate for any disputed, contingent or unforeseen liabilities or obligations of the Company, provided that any such reserves must be paid over by such
Person to an independent escrow 

  
 8 

 
agent, to be held by such agent or its successor for such period as such Person deems advisable for the purpose of applying such reserves to the payment of such liabilities or obligations and, at
the expiration of such period, the balance of such reserves, if any, must be distributed as hereinafter provided. 

(c) The remainder to the Members in accordance with and to the extent of their respective Capital Account balances after
taking into account the allocation of all Income or Loss pursuant to this Agreement for the fiscal year or years in which the Company is liquidated. 

4.3 Income, Losses and Distributive Shares of Tax Items. The Company’s Income or Loss, as the case may be, for each
fiscal year of the Company, as determined in accordance with such method of accounting as may be adopted for the Company pursuant to Article VI, will be allocated to the Members for both financial accounting and income tax purposes as set forth in
this Article IV, except as otherwise provided for herein or unless all Members agree otherwise. 
 4.4 Allocation of Income, Loss
and Credits. 
 (a) Income or Loss (other than from transactions in liquidation of the Company) and Credits for
each fiscal year will be allocated among the Members in accordance with their Percentage Interests. To the extent there is any change in the respective Percentage Interests of the Members during the year, Income, Loss and Credits will be allocated
among the pre-adjustment and post-adjustment periods as provided in Section 4.5(k). 

(b) Income from transactions in liquidation of the Company will be allocated among the Members in the following order of
priority: 
 (i) to those Members, if any, with negative Capital Account balances (determined prior to taking into
account any Distributions pursuant to Section 4.2) in the ratio that such negative balances bear to each other until all such Members’ Capital Account balances equal zero; then 

(ii) the remainder to the Members in accordance with their respective Percentage Interests. 

(c) Loss from transactions in liquidation of the Company will be allocated among the Members in the following order of
priority: 
 (i) to those Members, if any, with positive Capital Account balances (determined prior to taking into
account any Distributions pursuant to Section 4.2) in the ratio that such positive balances bear to each other until all such Members’ Capital Account balances equal zero; then 

(ii) the remainder to the Members in accordance with their respective Percentage Interests. 

  
 9 

 4.5 Special Rules Regarding Allocation of Tax Items. Notwithstanding
the foregoing provisions of Article IV, the following special rules apply in allocating tax items of the Company: 

(a) § 704(c) and Revaluation Allocations. In accordance with Code § 704(c) and
the Treasury Regulations thereunder, income, gain, loss and deduction with respect to any property contributed to the capital of the Company will, solely for tax purposes, be allocated among the Members so as to take account of any variation between
the adjusted basis of such property to the Company for federal income tax purposes and its Fair Value at the time of contribution. In the event of a Revaluation, subsequent allocations of income, gain, loss and deduction with respect to such
property will take account of any variation between the adjusted basis of such property to the Company for federal income tax purposes and its Fair Value immediately after the adjustment in the same manner as under Code § 704(c) and the
Treasury Regulations thereunder. Any elections or other decisions relating to such allocations must be made by the Management Committee in a manner that reasonably reflects the purpose and intention of this Agreement. Allocations pursuant to this
Section 4.5(a) are solely for income tax purposes and will not affect, or in any way be taken into account in computing, for book purposes, any Member’s Capital Account or share of Income or Loss, pursuant to any provision of this
Agreement. 
 (b) Minimum Gain Chargeback. Notwithstanding any other provision of this Article IV, if there is
a net decrease in Company Minimum Gain during a Company taxable year, each Member will be allocated items of income and gain for such year (and, if necessary, for subsequent years) in an amount equal to that Member’s share of the net decrease
in Company Minimum Gain during such year (hereinafter referred to as the “Minimum Gain Chargeback Requirement”). A Member’s share of the net decrease in Company Minimum Gain is the amount of the total decrease multiplied by the
Member’s percentage share of the Company Minimum Gain at the end of the immediately preceding taxable year. A Member is not subject to the Minimum Gain Chargeback Requirement to the extent: (i) the Member’s share of the net decrease
in Company Minimum Gain is caused by a guarantee, refinancing or other change in the debt instrument causing it to become partially or wholly recourse debt or a Member Nonrecourse Debt, and the Member bears the economic risk of loss for the newly
guaranteed, refinanced or otherwise changed liability; (ii) the Member contributes capital to the Company that is used to repay the Nonrecourse Debt and the Member’s share of the net decrease in Company Minimum Gain results from the
repayment; or (iii) the Minimum Gain Chargeback Requirement would cause a distortion and the Commissioner of the Internal Revenue Service waives such requirement. 

A Member’s share of Company Minimum Gain will be computed in accordance with Treasury Regulation § 1.704-2(g) and as of the end of any Company taxable year will equal: (1) the sum of the Nonrecourse Deductions allocated to that Member up to that time and the distributions made to that Member up
to that time of proceeds of a Nonrecourse Debt allocable to an increase of Company Minimum Gain, minus (2) the sum of that Member’s aggregate share of net decrease in Company Minimum Gain plus that Member’s aggregate share of
decreases resulting from revaluations of Property subject to Nonrecourse Debts. In addition, a Member’s share of Company Minimum Gain will be adjusted for the conversion of recourse and Member Nonrecourse Debts into Nonrecourse Debts in
accordance with Treasury Regulation § 1.704-2(g)(3). In computing the above, amounts allocated or distributed to the Member’s predecessor in interest will be taken into account. 

  
 10 

 (c) Member Minimum Gain Chargeback. Notwithstanding any other
provision of this Article IV other than Section 4.5(b), if there is a net decrease in Member Minimum Gain during a Company taxable year, each Member who has a share of the Member Minimum Gain (determined under Treasury Regulation § 1.704-2(i)(5) as of the beginning of the year) will be allocated items of income and gain for such year (and, if necessary, for subsequent years) equal to that Member’s share of the net decrease in
Member Minimum Gain. In accordance with Treasury Regulation § 1.704-2(i)(4), a Member is not subject to this Member Minimum Gain Chargeback requirement to the extent the net decrease in Member
Minimum Gain arises because the liability ceases to be Member Nonrecourse Debt due to a conversion, refinancing or other change in the debt instrument that causes it to be partially or wholly a Nonrecourse Debt. The amount that would otherwise be
subject to the Member Minimum Gain Chargeback requirement is added to the Member’s share of Company Minimum Gain. 

(d) Qualified Income Offset. If any Member unexpectedly receives an adjustment, allocation or distribution
described in Treasury Regulation § 1.704-1(b)(2)(ii)(d)(4), (5) or (6), that causes or increases such Member’s Adjusted Capital Account Deficit, items of Company income and gain will be
specially allocated to such Member in an amount and manner sufficient to eliminate such Adjusted Capital Account Deficit as quickly as possible, provided that an allocation under this Section 4.5(d) may be made if and only to the extent such
Member would have an Adjusted Capital Account Deficit after all other allocations under this Article IV have been made. 

(e) Nonrecourse Deductions. Nonrecourse Deductions for any fiscal year or other period will be allocated to the
Members in proportion to their Percentage Interests. 
 (f) Member Nonrecourse Deductions. Any Member
Nonrecourse Deductions will be allocated to the Member who bears the risk of loss with respect to the loan to which such Member Nonrecourse Deductions are attributable in accordance with Treasury Regulation
§ 1.704-2(i). 
 (g) Curative Allocations. Any special
allocations of items of income, gain, deduction or loss pursuant to Sections 4.5(b), (c), (d), (e) and (f) will be taken into account in computing subsequent allocations of income and gain pursuant to this Article IV, so that the net amount of
any items so allocated and all other items allocated to each Member pursuant to this Article IV are, to the extent possible, equal to the net amount that would have been allocated to each such Member pursuant to the provisions of this Article IV if
such adjustments, allocations or distributions had not occurred. In addition, allocations pursuant to this Section 4.5(g) with respect to Nonrecourse Deductions in Section 4.5(e) and Member Nonrecourse Deductions in Section 4.5(f)
will be deferred to the extent the Members reasonably determine that such allocations are likely to be offset by subsequent allocations of Company Minimum Gain or Member Minimum Gain, respectively. 

  
 11 

 (h) Loss Allocation Limitation. Notwithstanding the other
provisions of this Article IV, unless otherwise agreed to by all of the Members, no Member may be allocated Loss in any taxable year that would cause or increase an Adjusted Capital Account Deficit as of the end of such taxable year. 

(i) Share of Nonrecourse Liabilities. Solely for purposes of determining a Member’s proportionate share of
the “excess nonrecourse liabilities” of the Company within the meaning of Treasury Regulation § 1.752-3(a)(3), each Member’s interest in Company profits is equal to such Member’s
respective Percentage Interest. 
 (j) Compliance with Treasury Regulations. The foregoing provisions of this
Section 4.5 are intended to comply with Treasury Regulation §§ 1.704-1(b), 1.704-2 and 1.752-1 through 1.752-5, and must be interpreted and applied in a manner consistent with such Treasury Regulations. If it is determined by the Members that it is prudent or advisable to amend this Agreement in order comply with
such Treasury Regulations, the Management Committee, upon being so directed by the Members, is empowered to amend or modify this Agreement, notwithstanding any other provision of this Agreement. 

(k) General Allocation Provisions. Except as otherwise provided in this Agreement, all items that are components
of Income or Loss will be divided among the Members in the same proportions as they share such Income or Loss, as the case may be, for the year. For purposes of determining the Income, Loss or any other items for any period, Income, Loss or any such
other items will be determined on a daily, monthly or other basis, as determined by the Management Committee using any permissible method under Code § 706 and the Treasury Regulations thereunder. 

4.6 Withholding of Distributions. Notwithstanding any other provision of this Agreement, the Management Committee (or any
Person required or authorized by law to wind up the Company’s affairs) may suspend, reduce or otherwise restrict Distributions of Available Cash and Liquidation Proceeds when, in its sole opinion, such action is in the best interests of the
Company. 
 4.7 No Priority. Except as may be otherwise expressly provided herein, no Member has priority over any
other Member as to Company capital, income, gain, deductions, loss, credits or distributions. 
 4.8 Tax Withholding.
Notwithstanding any other provision of this Agreement, the Management Committee is authorized to take any action that it determines to be necessary or appropriate to cause the Company to comply with any withholding requirements established under any
federal, state or local tax law, including withholding on any Distribution to any Member. For all purposes of this Article IV, any amount withheld on any Distribution and paid over to the appropriate governmental body will be treated as if such
amount had in fact been distributed to the Member. 

  
 12 

 4.9 Reserves. The Management Committee may establish, maintain and
expend Reserves to provide for working capital, for future maintenance, repair or replacement of the Property, for debt service, for future investments and for such other purposes as the Management Committee may deem necessary or advisable. 

ARTICLE V—MANAGEMENT 

5.1 Management. The business and affairs of the Company will be managed by four natural persons elected by the Members
who are referred to as “Managers” and who, acting as a board, constitute the “Management Committee.” Each Manager will hold office until such Manager’s successor is duly elected by the Members or until such
Manager’s earlier death or resignation. Managers need not be Members of the Company. Except as expressly limited by law, the Certificate or this Agreement, the Property and the business of the Company will be controlled and managed by the
Management Committee. The Management Committee has and is vested with all powers and authorities, except as expressly limited by law, the Certificate, or this Agreement, to do or cause to be done any and all lawful things for and in behalf of the
Company, to exercise or cause to be exercised any or all of its powers, privileges and franchises, and to seek the effectuation of its objects and purposes. From time to time, the Management Committee may, but is not required to, elect one of the
Managers to serve as the “Presiding Manager.” The Presiding Manager will manage the day-to-day operations of the Company and will carry out the
decisions of the Management Committee. 
 5.2 Election of the Management Committee. Wayne Carter, Gary Wood, Tom
Zindrick and James Tyree are hereby elected by the Members to serve on the Management Committee until their successors have been duly elected or until their earlier death or resignation. Elections of Managers are not required to be held at any
regular frequency, but, instead, will be held upon the call of Members holding not less than 20% of the Percentage Interests. In electing Managers, each Member may cast as many votes in the aggregate as equals the Percentage Interest held by such
Member multiplied by the number of Managers to be elected at such election, and such Member may cast the whole number of votes for one candidate or distribute them among two or more candidates. Vacancies on the Management Committee may be filled by
an election held at a meeting of Members. 
 5.3 Meetings of the Management Committee; Place of Meetings. Meetings of
the Management Committee are not required to be held at any regular frequency, but, instead, will be held upon the call of any two of the Managers. All meetings of the Management Committee will be held at the principal office of the Company or at
such other place, either within or without the State of Delaware, as is designated by the Managers calling the meeting and stated in the notice of the meeting or in a duly executed waiver of notice thereof. Managers may participate in a meeting of
the Management Committee by means of conference telephone equipment or similar communications equipment whereby all Managers participating in the meeting can hear each other and participation in a meeting in this manner constitutes presence in
person at the meeting. 
 5.4 Quorum; Voting Requirement. At all meetings of the Management Committee, a majority of
the number of Managers then serving will constitute a quorum for the transaction of business. The act of a majority in number of the Managers present at any meeting of the Management Committee at which a quorum is present will be the act of the
Management Committee. 

  
 13 

 5.5 Notice of Meeting. Notice of each meeting of the Management
Committee, stating the place, day and hour of the meeting must be given to each Manager at least three days before the day on which the meeting is to be held. The notice may be given by any Manager having authority to call the meeting.
“Notice” and “call” with respect to such meetings are deemed to be synonymous. 
 5.6 Waiver of
Notice. Whenever any notice is required to be given to any Manager under the provisions of this Agreement, a waiver thereof in writing signed by such Manager, whether before or after the time stated therein, is deemed equivalent to the
giving of such notice. Attendance of a Manager at any meeting constitutes a waiver of notice of such meeting except where a Manager attends a meeting for the express purposes of objecting to the transaction of any business because the meeting is not
lawfully called or convened. 
 5.7 Action Without a Meeting. Any action that is required to be or may be taken at a
meeting of the Management Committee may be taken without a meeting if consents in writing, setting forth the action so taken, are signed by all of the Managers. The consents will have the same force and effect as a unanimous vote at a meeting duly
held. 
 5.8 Compensation of Managers. Managers may not receive any compensation for their services as such, unless
approved by a Super-Majority in Interest. Nothing herein contained may be construed to preclude any Manager from serving the Company in any other capacity and receiving compensation therefor. 

5.9 Restrictions on Authority of Management Committee. The Management Committee is not authorized to act in connection
with the following: 
 (a) the approval of a merger or consolidation with another Person; 

(b) change of the status of the Company from one in which management is vested in the Management Committee to one in
which management is vested in the Members; 
 (c) the sale, lease, exchange, or other disposition, other than by
mortgage, deed of trust, or pledge, of all, or substantially all, the Property, with or without the goodwill of the Company; or 

(d) determine, modify, compromise or release the amount and character of the contributions that a Member makes as the
consideration for the issuance of an Interest. 
 The approval of a Super-Majority in Interest is required for the foregoing transactions. 

5.10 Meetings of Members; Place of Meetings. Meetings of the Members are not required to be held on any regular
frequency. Meetings of the Members may be held for any purpose or purposes, unless otherwise prohibited by law or by the Certificate, and may be called by the Members holding not less than 20% of the Percentage Interests. All meetings of the Members
will be held at the principal office of the Company or at such other place, within or without the State of Delaware, as is designated from time to time by the Members and stated in the notice of the meeting or in a duly executed waiver of the notice
thereof. Members may participate in a meeting of the Members by means of conference telephone or similar communications equipment whereby all Members participating in the meeting can hear each other and participation in a meeting in this manner
constitutes presence in person at the meeting. 

  
 14 

 5.11 Quorum; Voting Requirement. The presence, in person or by proxy,
of a Majority in Interest constitutes a quorum for the transaction of business by the Members. If less than a Majority in Interest are represented at a meeting, a majority of the Interests so represented may adjourn the meeting to a specified date
not longer than 90 days after such adjournment, without further notice. At such adjourned meeting at which a quorum is present or represented by proxy, any business may be transacted that might have been transacted at the meeting as originally
noticed. The Members present at a duly convened meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough Members to constitute less than a quorum. Each Member may vote in accordance with such
Member’s Percentage Interest. The affirmative vote of a Majority in Interest will constitute a valid decision of the Members, except where a larger vote is required by the Act, the Certificate or this Agreement. At any time that no Person has
the right to vote or to participate in the management of the business and affairs of the Company with respect to a particular Interest, then the Percentage Interest represented by such Interest will be disregarded for the purposes of determining
whether a quorum is present at a meeting of Members and in determining whether the requisite Percentage Interest necessary for a valid decision of the Members has been obtained. 

5.12 Proxies. At any meeting of the Members, every Member having the right to vote thereat will be entitled to vote in
person or by proxy appointed by an instrument in writing signed by such Member and bearing a date not more than three years prior to such meeting. 

5.13 Action Without Meeting. Any action required or permitted to be taken at any meeting of the Members of the Company
may be taken without a meeting if the action is evidenced by one or more written consents setting forth the action to be taken and signed by each Member entitled to vote. 

5.14 Notice of Meetings. Written notice stating the place, day, hour and the purpose for which the meeting is called must
be given, not less than ten days nor more than 60 days before the date of the meeting, by or at the direction of the Members calling the meeting, to each Member entitled to vote at such meeting. A Member’s attendance at a meeting: 

(a) waives objection to lack of notice or defective notice of the meeting, unless such Member, at the beginning of the
meeting, objects to holding the meeting or transacting business at the meeting; and 
 (b) waives objection to
consideration of a particular matter at the meeting that is not within the purpose or purposes described in the notice of meeting, unless such Member objects to considering the matter when it is presented. 

5.15 Waiver of Notice. When any notice is required to be given to any Member of the Company hereunder, a waiver thereof
in writing signed by the Person entitled to such notice, whether before, at, or after the time stated therein, is equivalent to the giving of such notice. 

  
 15 

 5.16 Documents Filed with Delaware Secretary of State. Any Member or
Manager may execute and file with the Secretary of State of Delaware any document permitted or required by the Act. Such documents may be executed and filed only after the Members or the Management Committee have approved or consented to such action
in the manner provided herein. 
 5.17 Voting by Certain Holders. In the case of a Member that is a corporation, its
Interest may be voted by such officer, agent or proxy as the bylaws of such corporation may prescribe, or, in the absence of such provision, as the board of directors of such corporation may determine. In the case of a Member that is a general or
limited partnership, its Interest may be voted, in person or by proxy, by such Person as is designated by such Member. In the case of a Member that is another limited liability company, its Interest may be voted, in person or by proxy, by such
Person as is designated by the operating agreement of such other limited liability company, or, in the absence of such designation, by such Person as is designated by the limited liability company. 

5.18 Limitation of Liability; Indemnification. 

(a) Limitation. No Person will be liable to the Company or its Members for any loss, damage, liability or expense
suffered by the Company or its Members on account of any action taken or omitted to be taken by such Person as a Manager of the Company or by such Person while serving at the request of the Company as a director, officer or in any other comparable
position of any Other Enterprise, if such Person discharges such Person’s duties in good faith, exercising the same degree of care and skill that a prudent person would have exercised under the circumstances in the conduct of such prudent
person’s own affairs, and in a manner such Person reasonably believes to be in the best interest of the Company. A Manager’s liability hereunder is limited only for those actions taken or omitted to be taken by such Manager in the
discharge of such Manager’s obligations for the management of the business and affairs of the Company. The provisions of this Section are not intended to limit the liability of any Manager for any obligations of such Manager undertaken in this
Agreement in such Manager’s capacity as a Member. 
 (b) Right to Indemnification. The Company will
indemnify each Person who has been or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, investigative or appellate (regardless of whether such
action, suit or proceeding is by or in the right of the Company or by third parties) by reason of the fact that such Person is or was a Member or Manager of the Company, or is or was serving at the request of the Company as a director, officer or in
any other comparable position of any Other Enterprise against all liabilities and expenses, including judgments, amounts paid in settlement, attorneys’ fees, excise taxes or penalties, fines and other expenses, actually and reasonably incurred
by such Person in connection with such action, suit or proceeding (including the investigation, defense, settlement or appeal of such action, suit or proceeding); provided, however, that the Company is not required to indemnify or advance expenses
to any Person from or on account of such Person’s conduct that was finally adjudged to have been knowingly fraudulent, deliberately dishonest or willful misconduct; provided, further, that the Company is not required to indemnify or advance
expenses to any Person in connection with an action, suit or proceeding initiated by such Person unless the initiation of such 

  
 16 

 
action, suit or proceeding was authorized in advance by the Management Committee; provided, further, that a Manager will be indemnified hereunder only for those actions taken or omitted to be
taken by such Manager in the discharge of such Manager’s obligations for the management of the business and affairs of the Company and that the provisions of this Section 5.18 are not intended to extend indemnification to any Manager for
any obligations of such Manager undertaken in this Agreement in such Manager’s capacity as a Member. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or under a plea of nolo contendere or its
equivalent, will not, of itself, create a presumption that such Person’s conduct was finally adjudged to have been knowingly fraudulent, deliberately dishonest or willful misconduct. 

(c) Enforcement of Indemnification. If the Company refuses to indemnify any Person who may be entitled to be
indemnified or to have expenses advanced under this Section 5.18, such Person may maintain an action in any court of competent jurisdiction against the Company to determine whether or not such Person is entitled to such indemnification or
advancement of expenses hereunder. If such court action is successful and the Person is determined to be entitled to such indemnification or advancement of expenses, such Person will be reimbursed by the Company for all fees and expenses (including
attorneys’ fees) actually and reasonably incurred in connection with any such action (including the investigation, defense, settlement or appeal of such action). 

(d) Advancement of Expenses. Expenses (including attorneys’ fees) reasonably incurred in defending an
action, suit or proceeding, whether civil, criminal, administrative, investigative or appellate, will be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of
such Person to repay such amount if it is ultimately determined that such Person is not entitled to indemnification by the Company. In no event may any advance be made in instances where the Management Committee or independent legal counsel
reasonably determines that such Person would not be entitled to indemnification hereunder. 
 (e) Non-Exclusivity. The indemnification and the advancement of expenses provided by this Section 5.18 are not exclusive of any other rights to which those seeking indemnification or advancement of expenses may
be entitled under any statute, or any agreement, vote of Members, policy of insurance or otherwise, both as to action in their official capacity and as to action in another capacity while holding their respective offices, and do not limit in any way
any right that the Company may have to make additional indemnifications with respect to the same or different Persons or classes of Persons. The indemnification and advancement of expenses provided by, or granted pursuant to, this Section 5.18
will continue as to a Person who has ceased to be a Member or Manager of the Company, and as to a Person who has ceased serving at the request of the Company as a director, officer or in any other comparable position of any Other Enterprise and will
inure to the benefit of the heirs, executors and administrators of such Person. 
 (f) Insurance. Upon the
approval of the Management Committee, the Company may purchase and maintain insurance on behalf of any Person who is or was a Member, Manager, agent or employee of the Company, or is or was serving at the request of the Company as a director,
officer or in any other comparable position of any Other 

  
 17 

 
Enterprise, against any liability asserted against such Person and incurred by such Person in any such capacity, or arising out of such Person’s status as such, whether or not the Company
would have the power, or the obligation, to indemnify such Person against such liability under the provisions of this Section 5.18. 

(g) Amendment and Vesting of Rights. Notwithstanding any other provision of this Agreement, the terms and
provisions of this Section 5.18 may not be amended or repealed and the rights to indemnification and advancement of expenses created hereunder may not be changed, altered or terminated except by the approval of a Super-Majority in Interest. The
rights granted or created hereby are vested in each Person entitled to indemnification hereunder as a bargained-for, contractual condition of such Person’s being or serving or having served as a Member or
Manager of the Company or serving at the request of the Company as a director, officer or in any other comparable position of any Other Enterprise and, while this Section 5.18 may be amended or repealed, no such amendment or repeal will
release, terminate or adversely affect the rights of such Person under this Section 5.18 with respect to any act taken or the failure to take any act by such Person prior to such amendment or repeal or with respect to any action, suit or
proceeding with respect to such act or failure to act filed after such amendment or repeal. 
 (h) Definitions.
For purposes of this Section 5.18, references to: 
 (i) The “Company” includes, in addition to
the resulting or surviving limited liability company (or other entity), any constituent limited liability company (or other entity) (including any constituent of a constituent) absorbed in a consolidation or merger so that any Person who is or was a
member or manager of such constituent limited liability company (or other entity), or is or was serving at the request of such constituent limited liability company (or other entity) as a director, officer or in any other comparable position of any
Other Enterprise will stand in the same position under the provisions of this Section 5.18 with respect to the resulting or surviving limited liability company (or other entity) as such Person would if such Person had served the resulting or
surviving limited liability company (or other entity) in the same capacity; 
 (ii) “Other
Enterprises” or “Other Enterprise” include any other limited liability company, corporation, partnership, joint venture, trust or employee benefit plan; 

(iii) “fines” includes any excise taxes assessed against a person with respect to an employee benefit
plan; 
 (iv) “defense” includes investigations of any threatened, pending or completed action, suit
or proceeding as well as appeals thereof and also includes any defensive assertion of a cross-claim or counterclaim; and 

(v) “serving at the request of the Company” includes any service as a director, officer or in any other
comparable position that imposes duties on, or involves services by, a Person with respect to an employee benefit plan, its 

  
 18 

 
participants, or beneficiaries; and a Person who acted in good faith and in a manner such Person reasonably believed to be in the interest of the participants and beneficiaries of an employee
benefit plan will be deemed to have acted “in the best interest of the Company” as referred to in this Section 5.18. 

(i) Severability. If any provision of this Section 5.18 or the application of any such provision to any
Person or circumstance is held invalid, illegal or unenforceable for any reason whatsoever, the remaining provisions of this Section 5.18 and the application of such provision to other Persons or circumstances will not be affected thereby and,
to the fullest extent possible, the court finding such provision invalid, illegal or unenforceable must modify and construe the provision so as to render it valid and enforceable as against all Persons and to give the maximum possible protection to
Persons subject to indemnification hereby within the bounds of validity, legality and enforceability. Without limiting the generality of the foregoing, if any Member or Manager of the Company or any Person who is or was serving at the request of the
Company as a director, officer or in any other comparable position of any Other Enterprise, is entitled under any provision of this Section 5.18 to indemnification by the Company for some or a portion of the judgments, amounts paid in
settlement, attorneys’ fees, ERISA excise taxes or penalties, fines or other expenses actually and reasonably incurred by any such Person in connection with any threatened, pending or completed action, suit or proceeding (including the
investigation, defense, settlement or appeal of such action, suit or proceeding), whether civil, criminal, administrative, investigative or appellate, but not, however, for all of the total amount thereof, the Company will nevertheless indemnify
such Person for the portion thereof to which such Person is entitled. 
 5.19 Contracts with Members, Managers, or Their
Affiliates. No contract or transaction between the Company and one of its Members or Managers or between the Company and any Person in which one of its Members or Managers is a director or officer, or has a financial interest, will be
void or voidable solely for this reason, or solely because such Member or Manager is present at or participates in any meeting of the Members or Management Committee at which the contract or transaction is authorized, or solely because such
Member’s or Manager’s vote is counted for such purpose, if, in connection with any such meeting of the Members, the material facts as to such Member’s or Manager’s relationship are known to the Members and the Members holding a
majority of the Percentage Interests held by those Members who are disinterested with respect to such contract or transaction authorize such contract or transaction, even though the disinterested Members are less than a quorum, or if, in connection
with any such meeting of the Management Committee, the material facts as to such Member’s or Manager’s relationship are known to the Management Committee, and the majority of the Managers who are disinterested with respect to such contract
or transaction authorize such contract or transaction, even though the disinterested Managers are less than a quorum. Interested Members or Managers may be counted in determining the presence of a quorum at a meeting of the Members or Management
Committee at which the contract or transaction is authorized. 
 5.20 Other Business Ventures. Any Member or Manager
may engage in, or possess an interest in, other business ventures of every nature and description, independently or with others, whether or not similar to or in competition with the business of the Company, and neither the Company nor the Members
will have any right by virtue of this Agreement in or to such other 

  
 19 

 
business ventures or to the income or profits derived therefrom. Neither the Members nor the Managers are required to devote all of their time or business efforts to the affairs of the Company,
but will devote so much of their time and attention to the Company as is reasonably necessary and advisable to manage the affairs of the Company to the best advantage of the Company. 

ARTICLE VI—ACCOUNTING AND BANK ACCOUNTS 

6.1 Fiscal Year. The fiscal year and taxable year of the Company will end on December 31 of each year, unless a
different year is required by the Code. 
 6.2 Books and Records. At all times during the existence of the Company, the
Company will cause to be maintained full and accurate books of account, which will reflect all Company transactions and be appropriate and adequate for the Company’s business. The books and records of the Company will be maintained at the
principal office of the Company. Each Member (or such Member’s designated representative) may, during ordinary business hours and upon reasonable notice, inspect and copy (at such Member’s own expense) all books and records of the Company.

 6.3 Financial Reports. 

(a) Within 75 days after the end of each fiscal year, there will be prepared and delivered to each Member: 

(i) a balance sheet as of the end of such year and related financial statements for the year then ended; and 

(ii) other pertinent information regarding the Company. 

(b) Within 75 days after the end of each fiscal year, there will be prepared and delivered to each Member all
information with respect to the Company necessary for the preparation of the Members’ Federal and state income tax returns. 
 6.4
Tax Returns and Elections; Tax Matters Representative. 
 (a) The Members hereby appoint Tammie Wahaus as the
“partnership representative” as provided in Code Section 6223(a) (the “Tax Matters Representative”). The Tax Matters Representative may resign at any time. The Tax Matters Representative may be removed at any time by
the Management Committee. In the event of the resignation or removal of the Tax Matters Representative, the Management Committee shall select a replacement. 

(b) The Tax Matters Representative is authorized to represent the Company in connection with all examinations of the
Company’s affairs by any federal, state, local or foreign taxing authority (a “Taxing Authority”), including resulting administrative and judicial proceedings, and to expend Company funds for professional services and costs
associated therewith. The Tax Matters Representative shall promptly notify the Members in writing of the commencement of any tax audit of the Company, upon receipt of a tax assessment and upon the receipt of a notice of final partnership adjustment,
and shall keep 

  
 20 

 
the Members reasonably informed of the status of any tax audit and resulting administrative and judicial proceedings. The Tax Matters Representative shall not take any actions in a tax audit or
proceeding, including extending the statute of limitations, filing a request for administrative adjustment, filing suit relating to any Company tax refund or deficiency, entering into any settlement agreement relating to items of income, gain, loss
or deduction of the Company, or making any elections or other determinations, without the approval of the Management Committee. 

(c) To the extent permitted by applicable law and regulations, the Tax Matters Representative will cause the Company to
annually elect out of the partnership audit procedures set forth in Subchapter C of Chapter 63 of the Code as amended by the BBA (the “Revised Partnership Audit Rules”) pursuant to Code Section 6221(b). For any year in which
applicable law and regulations do not permit the Company to elect out of the Revised Partnership Audit Rules, then within forty-five (45) days of any notice of final partnership adjustment, the Tax Matters Representative shall cause the Company
to elect the alternative procedure under Code Section 6226, and furnish to the Internal Revenue Service and each Member during the year or years to which the notice of final partnership adjustment relates a statement of the Member’s share
of any adjustment set forth in the notice of final partnership adjustment. 
 (d) Each Member agrees that such Member
shall not treat any Company item inconsistently on such Member’s federal, state, foreign or other income tax return with the treatment of the item on the Company’s return. Any deficiency for taxes imposed on any Member (including
penalties, additions to tax or interest imposed with respect to such taxes and any taxes imposed pursuant to Code Section 6226) will be paid by such Member and if required to be paid (and actually paid) by the Company, will be recoverable from
such Member. 
 (e) The Company shall defend, indemnify, and hold harmless the Tax Matters Representative against any
and all liabilities sustained as a result of any act or decision concerning Company tax matters and within the scope of the Tax Matters Representative’s responsibilities, so long as such act or decision was done or made in good faith and does
not constitute gross negligence or willful misconduct. 
 6.5 Section 754 Election. If a distribution of Company assets
occurs that satisfies the provisions of Section 734 of the Code or if a transfer of an Interest occurs that satisfies the provisions of Section 743 of the Code, upon the determination of the Management Committee, the Company will elect,
pursuant to Section 754 of the Code, to adjust the basis of the Property to the extent allowed by such Section 734 or 743 and will cause such adjustments to be made and maintained. 

6.6 Bank Accounts. All funds of the Company will be deposited in a separate bank, money market or similar account or
accounts approved by the Management Committee and in the Company’s name. Withdrawals therefrom may be made only by individuals authorized to do so by the Management Committee. 

  
 21 

 ARTICLE VII—TRANSFERS OF INTERESTS AND 

EVENTS OF WITHDRAWAL 

7.1 General Restrictions. Except as expressly provided in this Agreement, no Member may Transfer all or any part of such
Member’s Interest. Any purported Transfer of an Interest in violation of the terms of this Agreement will be null and void and of no effect. A permitted Transfer will be effective as of the date specified in the instruments relating thereto.
Any Transferee desiring to make a further Transfer will become subject to all of the provisions of this Article VII to the same extent and in the same manner as any Member desiring to make any Transfer. 

7.2 Permitted Transfers. Each Member (a “Transferor”) may Transfer (but not substitute the assignee as a
Substitute Member in such Member’s place, except in accordance with Section 7.3), by a written instrument, all or any part of such Member’s Interest, provided that the Transfer would not result in the “termination” of the
Company pursuant to § 708 of the Code. Any assignee of an Interest as allowed by this Section 7.2 who does not become a Substitute Member as provided in Section 7.3 (a “Transferee”) will not be a Member and will
not have any right to vote as a Member or to participate in the management of the business and affairs of the Company, such right to vote such Interest and to participate in the management of the business and affairs of the Company continuing with
the Transferor. The Transferee will, however, be entitled to distributions and allocations of the Company, as provided in Article IV, attributable to the Interest that is the subject of the Transfer to such Transferee. 

7.3 Substitute Members. No assignee of all or part of a Member’s Interest will become a Member in place of the
Transferor (a “Substitute Member”) unless and until: 
 (a) the Transferor (if living) has stated
such intention in the instrument of assignment; 
 (b) the Transferee has executed an instrument accepting and
adopting the terms and provisions of this Agreement; 
 (c) the Transferor or Transferee has paid all reasonable
expenses of the Company in connection with the admission of the Transferee as a Substitute Member; and 
 (d) the
Members holding a majority of the remaining Percentage Interests, in their sole and absolute discretion, have consented in writing to such Transferee becoming a Substitute Member. 

Upon satisfaction of all of the foregoing conditions with respect to a Transferee, the Management Committee will cause this Agreement to be duly amended to
reflect the admission of the Transferee as a Substitute Member. 
 7.4 Effect of Admission as a Substitute Member.
Unless and until admitted as a Substitute Member pursuant to Section 7.3, a Transferee is not entitled to exercise any rights of a Member in the Company, including the right to vote, grant approvals or give consents with respect to such
Interest, the right to require any information or accounting of the Company’s business or the right to inspect the Company’s books and records, but a Transferee will only be entitled to 

  
 22 

 
receive, to the extent of the Interest transferred to such Transferee, the Distributions to which the Transferor would be entitled. A Transferee who has become a Substitute Member has, to the
extent of the Interest transferred to such Transferee, all the rights and powers of the Member for whom such Transferee is substituted and is subject to the restrictions and liabilities of a Member under this Agreement and the Act. Upon admission of
a Transferee as a Substitute Member, the Transferor will cease to be a Member of the Company to the extent of such Interest. A Person will not cease to be a Member upon assignment of all of such Member’s Interest unless and until the Transferee
becomes a Substitute Member. 
 7.5 Additional Members and Interests. Additional Members may be admitted to the Company
and additional Interests may be issued only upon the consent of a Super-Majority in Interest. Whenever any additional Member is admitted to the Company, or any additional Interest is issued, in accordance with this Section 7.5, the Percentage
Interest of each Member outstanding immediately prior to such admission or issuance will be decreased proportionately, as appropriate, to maintain the aggregate Percentage Interests of the Members at 100%. The Management Committee will cause
Schedule A to be amended to reflect any adjustment in the Percentage Interests of the Members in accordance with this Section 7.5. 

7.6 Redemption of Interests. Any Interest may be redeemed by the Company, by purchase or otherwise, upon the consent of
the holder of such Interest and of Members holding a majority of the Percentage Interests held by all Members other than the holder of the Interest to be redeemed. Whenever any Interest is redeemed by the Company in accordance with this
Section 7.6, the Percentage Interest of each Member outstanding immediately following such redemption will be increased proportionately, as appropriate, to maintain the aggregate Percentage Interests of the Members at 100%. The Management
Committee will cause Schedule A to be amended to reflect any adjustment in the Percentage Interests of the Members in accordance with this Section 7.6. 

7.7 Events of Withdrawal. A Member ceases to be a Member of the Company upon the occurrence of any of the following
events (an “Event of Withdrawal”): 
 (a) A Member withdraws from the Company by giving 90 days prior
written notice of such Member’s withdrawal to the other Members, provided, however, such withdrawal constitutes a breach of this Agreement and such Member is liable to the Company for any damages sustained by the Company as a result of such
withdrawal and the Company may offset such damages against any amount otherwise distributable to such Member pursuant to Article IV; 

(b) A Member: 

(i) makes an assignment for the benefit of creditors; 

(ii) is the subject of a Bankruptcy; 

(iii) files a petition or answer seeking for such Member any reorganization, arrangement, composition, readjustment,
liquidation, or similar relief under any statute, law or regulation or files an answer or other pleading admitting or failing to contest the material allegations of a petition filed against such Member in a proceeding of such nature; or 

  
 23 

 (iv) seeks, consents to or acquiesces in the appointment of a
trustee, receiver or liquidator for such Member or of all or any substantial part of such Member’s property; 

(c) With respect to any Member, 120 days after the commencement of any proceeding against the Member seeking
reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any statute, law or regulation, the proceeding has not been dismissed, or if, within 90 days after the appointment, without such Member’s
consent or acquiescence, of a trustee, receiver or liquidator of the Member or of all or any substantial part of such Member’s property, the appointment is not vacated or stayed, or, within 90 days after the expiration of any such stay, the
appointment is not vacated; 
 (d) In the case of a Member who is a natural person: 

(i) such Member’s death; or 

(ii) the entry by a court of competent jurisdiction adjudicating such Member incapacitated to manage such Member’s
person or estate; 
 (e) In the case of a Member that is a trust, the termination of the trust or a distribution of
its entire interest in the Company but not merely the substitution of a new trustee; 
 (f) In the case of a Member
that is a general or limited partnership, the dissolution and commencement of winding up of the partnership or a distribution of its entire interest in the Company; 

(g) In the case of a Member that is a corporation, the filing of a certificate of dissolution, or its equivalent, for
the corporation or revocation of its charter or a distribution of its entire interest in the Company; 
 (h) In the
case of a Member that is an estate, the distribution by the fiduciary of the estate’s entire interest in the Company; or 

(i) In the case of a Member that is a limited liability company, the filing of a certificate of dissolution or
termination, or its equivalent, for the limited liability company or a distribution of its entire interest in the Company. 
 Except as provided in
Section 8.1(c), upon the occurrence of an Event of Withdrawal, the Company will not be dissolved and the Member with respect to whom an Event of Withdrawal has occurred, or the Person succeeding to the interest of the Member with respect to
whom an Event of Withdrawal has occurred, as the case may be, will be deemed to be a Transferee under the provisions of Section 7.2, and the rights and obligations of such Member or such Person will be governed by Section 7.2; provided,
however, that such Member or Person will thereafter have no 

  
 24 

 
right to vote as a Member or to participate in the management of the business and affairs of the Company as a Member. Such Member’s, or such Person’s, right to receive Distributions, as
set forth in Section 7.2, are in lieu of any rights that such Member, or such Person, may have to receive the Fair Value of such Member’s Interest as provided by the Act. 

ARTICLE VIII—DISSOLUTION AND TERMINATION 

8.1 Events Causing Dissolution. The Company will be dissolved upon the first to occur of the following events: 

(a) an Event of Withdrawal with respect to the sole remaining Member. 

(b) upon the approval of a Super-Majority in Interest. 

(c) upon the entry of a decree of judicial dissolution under Section 18-802
of the Act. 
 (d) when the Company is not the surviving entity in a merger or consolidation under the Act. 

8.2 Effect of Dissolution. Except with respect to the occurrence of an event referred to in Section 8.1(e), and
except as otherwise provided in this Agreement, upon the dissolution of the Company, the Management Committee will take such actions as may be required pursuant to the Act and will proceed to wind up, liquidate and terminate the business and affairs
of the Company. In connection with such winding up, the Management Committee may liquidate and reduce to cash (to the extent necessary or appropriate) the assets of the Company as promptly as is consistent with obtaining Fair Value therefor, apply
and distribute the proceeds of such liquidation and any remaining assets in accordance with the provisions of Section 8.3, and do any and all acts and things authorized by, and in accordance with, the Act and other applicable laws for the
purpose of winding up and liquidation. 
 8.3 Application of Proceeds. Upon dissolution and liquidation of the Company,
the assets of the Company will be applied and distributed in the order of priority set forth in Section 4.2. 
 ARTICLE
IX—MISCELLANEOUS 
 9.1 Title to the Property. Title to the Property will be held in the name of the Company.
No Member has any ownership interest or rights in the Property, except indirectly by virtue of such Member’s ownership of an Interest. No Member has any right to seek or obtain a partition of the Property, nor does any Member have the right to
any specific assets of the Company upon the liquidation of or any distribution from the Company. 
 9.2 Nature of Interest in the
Company. An Interest is personal property for all purposes. 

  
 25 

 9.3 Organizational Expenses. Each Member will pay such Member’s
own expenses incurred in connection with the creation and formation of the Company and review and negotiation of this Agreement. 

9.4 Notices. Any notice, demand, request or other communication (a “Notice”) required or permitted to be
given by this Agreement or the Act to the Company, any Member, or any other Person will be sufficient if in writing and if hand delivered or mailed by registered or certified mail to the Company at its principal office or to a Member or any other
Person at the address of such Member or such other Person as it appears on the records of the Company or sent by facsimile transmission to the telephone number, if any, of the recipient’s facsimile machine as such telephone number appears on
the records of the Company. All Notices that are mailed will be deemed to be given when deposited in the United States mail, postage prepaid. All Notices that are hand delivered will be deemed to be given upon delivery. All Notices that are given by
facsimile transmission will be deemed to be given upon receipt, it being agreed that the burden of proving receipt will be on the sender of such Notice and such burden will not be satisfied by a transmission report generated by the sender’s
facsimile machine. 
 9.5 Waiver of Default. No consent or waiver, express or implied, by the Company or a Member with
respect to any breach or default by another Member hereunder will be deemed or construed to be a consent or waiver with respect to any other breach or default by such Member of the same provision or any other provision of this Agreement. Failure on
the part of the Company or a Member to complain of any act or failure to act of another Member or to declare such other Member in default will not be deemed or constitute a waiver by the Company or the Member of any rights hereunder. 

9.6 No Third Party Rights. None of the provisions contained in this Agreement are for the benefit of or enforceable by
any third parties, including creditors of the Company; provided, however, the Company may enforce any rights granted to the Company under the Act, the Certificate, or this Agreement. 

9.7 Entire Agreement. This Agreement, together with the Certificate, constitutes the entire agreement between the
Members, in such capacity, relative to the formation, operation and continuation of the Company. 
 9.8 Amendments to this
Agreement. 
 (a) Except as otherwise provided herein, this Agreement may not be modified or amended in any manner
other than by the written agreement of a Super-Majority in Interest at the time of such modification or amendment. 

(b) This Agreement may be amended by the Management Committee, without any execution of such amendment by the Members,
in order to reflect the occurrence of any of the following events provided that all of the conditions, if any, contained in the relevant sections of this Agreement with respect to such event have been satisfied: 

(i) an adjustment of the Percentage Interests of the Members upon making a Capital Contribution (Section 3.2), upon the
admission of an additional Member or issuance of an additional Interest (Section 7.5), or upon the redemption of an Interest (Section 7.6); 

  
 26 

 (ii) the modification of this Agreement to comply with the relevant
tax laws pursuant to Sections 3.3 or 4.5(j); and 
 (iii) the admission of a Substitute Member (Section 7.3). 

(c) Anything in this Section 9.8 to the contrary notwithstanding, without the written consent of all Members, no
amendment to this Agreement may: 
 (i) add to, detract from or otherwise modify the purposes of the Company as set
forth in Section 2.1; 
 (ii) enlarge the obligations of any Member under this Agreement; 

(iii) amend any provisions of Article IV other than an amendment to comply with the relevant tax laws as provided in
Section 4.5(j); or 
 (iv) amend this Section 9.8 or any provision of this Agreement requiring the consent
of a Super-Majority in Interest. 
 9.9 Severability. If any provision of this Agreement is held to be illegal, invalid
or unenforceable to any extent, the legality, validity and enforceability of the remainder of this Agreement will not be affected thereby and will remain in full force and effect and may be enforced to the greatest extent permitted by law. 

9.10 Binding Agreement. Subject to the restrictions on the disposition of Interests herein contained, the provisions of
this Agreement are binding upon, and will inure to the benefit of, the parties hereto and their respective heirs, personal representatives, successors and permitted assigns. 

9.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which is deemed to be an
original and all of which constitute one agreement that is binding upon all of the parties hereto, notwithstanding that all parties are not signatories to the same counterpart. 

9.12 Governing Law. This Agreement is governed by, and is to be construed in accordance with, the laws of the State of
Delaware. 
 9.13 Remedies. In the event of a default by any party in the performance of any obligation undertaken in
this Agreement, in addition to any other remedy available to the non-defaulting parties, the defaulting party must pay to each of the non-defaulting parties all costs,
damages, and expenses, including reasonable attorneys’ fees, incurred by the non-defaulting parties as a result of such default. If any dispute arises with respect to the enforcement, interpretation, or
application of this Agreement and court proceedings are instituted to resolve such dispute, the prevailing party in such court proceedings may recover from the non-prevailing party all costs and expenses,
including reasonable attorneys’ fees, incurred by the prevailing party in such court proceedings. 

  
 27 

 9.14 Legal Representation. The Members hereby acknowledge that this
Agreement was prepared by the law firm of Stinson LLP on behalf of the Company. Each Member hereby acknowledges that: 

(a) a conflict of interest may exist between such Member’s interests and those of the Company and the other
Members; 
 (b) such Member has had the opportunity to seek the advice of independent legal counsel; 

(c) this Agreement has tax consequences; and 

(d) such Member has had the opportunity to seek the advice of independent tax counsel. 

The parties hereto have executed this Agreement on the date first written above. 

 

			
	The Company:
	
	V2ACT THERAPEUTICS, LLC

 
			
		
	By:	 	/s/ Thomas D. Zindrick

 
			
	Name:	 	Thomas D. Zindrick

 
			
	Title:	 	President & CEO

  

			
	The Members:
	
	TVAX BIOMEDICAL, INC.

 
			
		
	By:	 	/s/ Gary W. Wood

 
			
	Name:	 	Gary W. Wood

 
			
	Title:	 	Chairman of the Board

 
			
	
	GENELUX CORPORATION

 
			
		
	By:	 	/s/ Thomas D. Zindrick

 
			
	Name:	 	Thomas D. Zindrick

 
			
	Title:	 	President & CEO

  
 28 

 SCHEDULE A 
  

									
	 Name and Address of Member
	  	Capital Contribution	 	  	Percentage Interest	 
	 TVAX Biomedical, Inc.
	  	$	____________	 	  	 	50	% 
	 Genelux Corporation

1177 Idaho Street, Suite 202

Redlands, CA 92374
	  	$	____________	 	  	 	50	% 
	 Totals:
	  	$	____________	 	  	 	100	%EX-10.16

 Exhibit 10.16 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 LICENSE AGREEMENT 

This LICENSE AGREEMENT (the “Agreement”) is entered into on June 18, 2021 (the “Effective Date”)
between: 
 TVAX Biomedical, Inc., a Delaware corporation with its principal place of business at 10900 S. Clay Blair Blvd., Suite 700 Olathe, KS 66061
(“Licensor”), and 
 V2ACT Therapeutics, LLC, a Delaware limited liability company with its principal place of business at
3030 Bunker Hill Street, Suite 310, San Diego, CA 92109 (“Licensee”). 
 Licensor and Licensee are sometimes referred to herein
individually as a “Party” and collectively as the “Parties.”  
 RECITALS 

WHEREAS, Licensor has developed certain proprietary cell therapy that may be useful in connection with
oncolytic virus for the treatment of cancer; 
 WHEREAS, Licensor and Genelux Corporation have formed
Licensee as a new company focused on the development and commercialization of cancer therapy product that combines Licensor’s proprietary cell therapy with oncolytic virus; 

WHEREAS, Licensor wishes to grant to Licensee, and Licensee desires to obtain, a license under the
Licensor’s intellectual property rights related to its proprietary cell therapy, on the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the foregoing premises and the mutual promises,
covenants and conditions contained in this Agreement, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used in
this Agreement, the following initially capitalized terms, whether used in the singular or plural form, shall have the meanings set forth in this Article 1. 

1.1 “Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control
with that Party. For the purpose of this definition, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual power, either directly or indirectly
through one or more intermediaries, to direct 

  
 1. 

 
or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stocking of such Person, by contract or otherwise;
provided however that Licensor and Licensee are not Affiliate of each other for the purpose of this Agreement. 
 1.2 “Change
of Control” means, with respect to a Party, (a) a merger, reorganization, consolidation or other transaction involving such Party and any entity that is not an Affiliate of such Party as of the Effective Date, which results in the
voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or other
transaction, or (b) any entity that is not an Affiliate of such Party as of the Effective Date becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party or otherwise
acquiring the power (whether through ownership interest, contractual right or otherwise) to direct or cause the direction of the management or policies of such Party. 

1.3 “Combination Therapy Patent” means the Patent Rights that are set forth in Exhibit A. 

1.4 “Commercially Reasonable Efforts” means those efforts consistent with the exercise of prudent scientific and
business judgment in an active and ongoing program as applied by a Party to the development and commercialization of its own products at a similar stage of development and with similar market potential. Commercially Reasonable Efforts requires that
a Party, at a minimum, assign responsibility for such obligations to qualified employees, set annual goals and objectives for carrying out such obligations, and allocate resources designed to meet such goals and objectives. 

1.5 “Confidential Information” means, with respect to a Party, all information that is disclosed by or on behalf of
such Party or its Affiliate to the other Party or its Affiliate under this Agreement, whether in oral, written, graphic, or electronic form. 

1.6 “Control” or “Controlled” means, with respect to any material, information, or intellectual
property right, that Licensor (or any of its Affiliate, but excluding Third Party that becomes an Affiliate of Licensor after the Effective Date as a result of a Change of Control of Licensor) owns or has a license to such material, information, or
intellectual property right and, in each case, has the ability to grant to Licensee access, a license, or a sublicense (as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any
then-existing agreement or other arrangement with any Third Party; provided however that if such material, information, or intellectual property right is in-licensed or acquired by Licensor from a Third Party,
then Licensor’s Control of such material, information, or intellectual property right shall be subject to Licensee’s agreement to (a) comply with the applicable terms and conditions of the agreement under which Licensor in-licensed or acquired such material, information, or intellectual property right; and (b) pay all amounts that Licensor would be obligated to pay in connection with the grant, maintenance or exercise of a
sublicense to Licensee under such material, information, or intellectual property right. 
 1.7 “Field” means the
diagnosis, prevention and treatment of cancer in humans. 

  
 2. 

 1.8 “Know-How” means any
proprietary information, including discoveries, improvements, modifications, processes, methods, protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise. 

1.9 “Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law
of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 
 1.10
“Licensed Know-How” means all Know-How that (a) is Controlled by Licensor as of the Effective Date or at any time during the Term; and (b) is
necessary or reasonably useful for the manufacture or use of the Licensed T Cell Therapeutic(s) as part of the Product. 
 1.11
“Licensed Patents” means all Patent Rights that (a) are Controlled by Licensor as of the Effective Date or at any time during the Term; and (b) claim the Licensed T Cell Therapeutic(s) (including composition of matter,
method of make and use); but excluding Combination Therapy Patents. Licensed Patents existing as of the Effective Date are set forth in Exhibit B. 

1.12 “Licensed Technology” means the Licensed Patents and Licensed Know-How.
 
 1.13 “Licensed T-Cell Therapeutic(s)” means
T-Cell Therapeutics Controlled by Licensor. 
 1.14 “Patent Rights” means
all patents and patent applications (which for the purpose of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals, revalidations, extensions, registrations, pediatric exclusivity
periods and supplemental protection certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing. 

1.15 “Person” means any individual, partnership, limited liability company, firm, corporation, association,
trust, unincorporated organization or other entity. 
 1.16 “Product” means any single product, procedure or method
for the treatment of cancer that combines the steps of administering to a patient, at different times or at the same time: (a) a Licensed T Cell Therapeutic(s), and (b) any Therapeutic Virus. 

1.17 “T-Cell Therapeutic(s)” means autologous or allogeneic cancer-specific T
lymphocytes produced for treatment of a cancer patient which, optionally, may be genetically engineered. Exemplary cancer-specific T lymphocytes include those produced by TVAX Immunotherapy, TIL immunotherapy, and
TCR/CAR-T immunotherapy. 
 1.18 “Territory” means worldwide. 

1.19 “Therapeutic Virus(es)” means virus-based cancer therapeutics, whether a virus (replicating-competent, -non-competent, or conditional replicating) by itself, or in mixture with, attached to or inside others (e.g., other virus, prokaryotic or eukaryotic cell, immune cell,
microorganism, protein/peptide, nucleic acid, nanoparticle, chemotherapeutic agent, diagnostic 

  
 3. 

 
agent, or other organic or inorganic materials). Exemplary virus-based therapeutics include oncolytic viruses (e.g., replication-competent viruses selected or engineered to preferentially infect
and kill cancer cells), vaccines and gene therapy products. 
 1.20 “Third Party” means any person or entity other
than Licensor or Licensee or an Affiliate of either of them. 
 1.21 Interpretations. In this Agreement, unless otherwise
specified: 
 (a) “includes” and “including” shall mean respectively includes and including without limitation;

 (b) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders;

 (c) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not
merely to the particular provision in which such words appear; and 
 (d) the Exhibits and other attachments form part of the
operative provision of this Agreement and references to this Agreement shall include references to the Exhibits and attachments. 

ARTICLE 2 
 LICENSE

 2.1 License Grant. Subject to the terms of this Agreement, Licensor hereby grants Licensee: 

(a) a non-exclusive, fully paid, royalty free license under the Licensed Technology to research,
develop, make, have made, use, sell, offer for sale, have sold, import and otherwise commercialize the Product in the Field in the Territory; and 

(b) an exclusive (even as to Licensor and its Affiliates), fully paid, royalty free license under the Combination Therapy Patent to
research, develop, make, have made, use, sell, offer for sale, have sold, import and otherwise commercialize the Product in the Field in the Territory. 

2.2 Sublicenses. Subject to the terms of this Agreement, Licensee shall have the right to grant sublicenses (through multiple
tiers) to its Affiliates, subcontractors and other Third Parties under its license in Section 2.1, provided that each sublicense shall be subject to and consistent with the terms and conditions under this Agreement and Licensee shall remain
primarily responsible for the performance of the obligations hereunder by each of its sublicensees. Except for sublicenses granted to Affiliates and subcontractors, Licensee shall promptly notify Licensor of the grant of any sublicense under this
Agreement. 
 2.3 No Implied License; Negative Covenant. Except as set forth herein, Licensee shall not acquire any license,
right or other interest, by implication or otherwise, under any intellectual property rights of Licensor. Licensee covenants that it will not, and it will not permit 

  
 4. 

 
any of its sublicensees to, use or practice any Licensed Technology and Combination Therapy Patents outside the Field. 

2.4 Non-Compete. 

(a) During the Term of this Agreement, neither Licensor nor any of its Affiliates (other than an Acquirer as set forth in
Section 2.4(b) below) shall, directly or indirectly, develop, commercialize, promote, make, have made, sell, offer for sale, import and/or export, or enter into any collaboration or license agreement with any Third Party in connection with the
development, commercialization, promotion, manufacture, sale, offering for sale, importation and/or exportation of, [***]; provided that the foregoing non-compete obligation shall no longer apply if [***] or,
[***] (for clarity, in such event, the license rights set forth in Sections 2.1 and 2.2 shall remain in full force and effect, and the license under Section 2.1(b) shall remain exclusive). For clarity, nothing herein shall limit or restrict
Licensor’s right to develop, commercialize or exploit [***]. 
 (b) If a Third Party becomes an Affiliate of Licensor after the
Effective Date as a result of a Change of Control of Licensor, then such new Affiliate of Licensor (“Acquirer”) may initiate or continue activities or programs that, if conducted by Licensor, would cause Licensor to violate the non-compete obligations set forth in Section 2.4(a) (an “Acquirer Program”); and such continuation or initiation of an Acquirer Program by the Acquirer will not constitute a violation of
Section 2.4(a), provided that the Acquiror conducts the Acquirer Program independent of Licensor’s Therapeutic Virus program and Licensor does not grant the Acquirer any right to use any Licensed Technology or Combination
Therapy Patent in such Acquirer Program. 
 ARTICLE 3 

DEVELOPMENT AND COMMERCIALZATION 

3.1 Overview. Subject to the terms and conditions of this Agreement, Licensee shall be solely responsible, either by itself or
through its sublicensees, for the research, development, manufacture and commercialization of the Products in the Field in the Territory. 

3.2 Diligence. Licensee shall use Commercially Reasonable Efforts to research, develop, manufacture and commercialize the
Products in the Field in the Territory. 
 3.3 Costs. Licensee shall be solely responsible for all costs and expenses incurred
in connection with the research, development, manufacture and commercialization of the Products in the Field in the Territory. 
 3.4
Reports. Licensee shall keep Licensor reasonably informed on the development and commercialization of the Products in the Field. Within [***] after the end of each calendar year, Licensee shall provide Licensor with a written report
summarizing its development and commercialization activities in such calendar year and its plan for the next calendar year. Upon Licensor’s reasonable request, Licensee shall discuss with Licensor the status, progress, results and plan of its
development and commercialization activities. 

  
 5. 

 ARTICLE 4 

SERVICES 
 4.1
Overview. Subject to the terms and conditions of this Agreement, Licensor agrees to undertake and perform certain research, development and/or manufacture services (the “Services”) related the Licensed T Cell Therapeutic(s)
in connection with the research, development and manufacture of the Products in the Field. 
 4.2 Work Order. From time to
time, Licensee may request Licensor to perform Service by submitting a work order (the “Work Order”) that sets forth the details of the Service, including the scope, requirement, specifications, deliverables, timeline, payment and
other terms of such Service. The Parties shall negotiate the terms of each Work Order in good faith. If the Parties reach agreement on the details of the Work Order, the Parties shall execute the Work Order, which shall be incorporated into this
Agreement and subject to the terms and conditions of this Agreement. In the event of a conflict between any Work Order and this Agreement, the terms of this Agreement shall prevail, unless the Work Order expressly refers to the Parties’ intent
to alter the terms of this Agreement with respect to that Work Order. Any modifications to an executed Work Order shall require the written agreement of both Parties. The Parties may also enter into a separate services agreement and/or supply
agreement. 
 4.3 Performance of Services. After the execution of a Work Order by the Parties, Licensor shall use Commercially
Reasonable Efforts to perform the Services set forth in such Work Order, in a timely and professional manner, and in compliance with all applicable Laws. 

4.4 Payment for Services. In consideration of Licensor’s performance of the Services, Licensee will pay Licensor the fees
(including costs and expenses) specified in the applicable Work Order in accordance with the payment schedule set forth therein. 

ARTICLE 5 
 PATENT
MATTERS 
 5.1 Prosecution and Enforcement of Licensed Patents. As between the Parties, Licensor shall have the sole right
and discretion to prepare, file, prosecute, maintain, enforce and defend the Licensed Patents, at Licensor’s own costs and expense. 

5.2 Prosecution of Combination Therapy Patents. 

(a) After the Effective Date, Licensee shall have the right to prosecute and maintain the Combination Therapy Patents (other than any
claims that do not claim any Product) at Licensee’s cost and expense. Licensee shall have the right to use patent counsel of its choosing and intends to retain Licensor’s patent counsel initially. Within [***] after the receipt of a
written notice from Licensee, Licensor shall (and shall cause its patent counsel to) transfer the patent prosecution of the Combination Therapy Patents (other than any claims that do not claim any Product) to Licensee’s patent counsel,
including relevant patent prosecution files, except that Licensor shall have the right to continue the prosecution and maintenance of any claims that do not claim any Product. 

  
 6. 

 (b) The Party that controls the prosecution and maintenance of the Combination
Therapy Patent pursuant to Section 5.2(a) (the “Prosecuting Party”) shall consult with the other Party and keep the other Party reasonably informed of the status of the Combination Therapy Patents and shall promptly provide the
other Party with all material correspondence received from any patent authority in connection therewith. In addition, the Prosecuting Party shall provide the other Party with drafts of all proposed material filings and correspondence to any patent
authority with respect to the Combination Therapy Patents for review and comment prior to the submission. The Prosecuting Party shall consider in good faith and use reasonable efforts to address the other Party’s comments prior to submitting
such filing and correspondences. 
 (c) The Prosecuting Party shall notify the other Party of any decision to cease prosecution or
maintenance of any Combination Therapy Patents in any country. The Prosecuting Party shall provide such notice at least [***] prior to any filing or payment due date, or any other due date that requires action, in connection with such Combination
Therapy Patent in such country. In such event, upon the other Party’s request, the Prosecuting Party shall transfer the prosecution and maintenance of such Combination Therapy Patent in such country to the other Party, and the other Party shall
have the right to continue the prosecution or maintenance of such Combination Therapy Patent in such country at its own cost and expense. 

(d) Each Party shall provide the other Party all reasonable assistance and cooperation in the patent prosecution efforts under this
Section 5.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution.  

5.3 Enforcement of Combination Therapy Patents. 

(a) Each Party shall promptly notify the other Party if it becomes aware of any alleged or threatened infringement by a Third Party of
any Combination Therapy Patents that involves the development, manufacture or commercialization of any product that combines T-Cell Therapeutics and Therapeutic Virus in the Field (the “Product
Infringement”). 
 (b) As between the Parties, Licensee shall have the first right to bring and control any legal action by
counsel of its choice in connection with any Product Infringement at its own expense and as it reasonably determines appropriate after consultation with Licensor. Licensor shall have the right to be represented in any such action by counsel of its
choice at its own expense. If Licensee does not to bring such legal action within [***] after the notice provided pursuant to Section 5.3(a), Licensor shall have the right to bring and control any legal action in connection with such Product
Infringement at its own expense as it reasonably determines appropriate after consultation with Licensee. 
 (c) At the request and
expense of the Party bringing the action under Section 5.3(b) above, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a
party to the action if required. In connection with any such proceeding, the Party bringing the action under Section 5.3(b) shall keep the other Party reasonably informed on the status of such action and shall not enter into any settlement
admitting the invalidity of, or otherwise impairing the other 

  
 7. 

 
Party’s rights in, the Combination Therapy Patents without the prior written consent of the other Party (not to be unreasonably withheld). 

(d) Any recoveries resulting from enforcement action under Section 5.3(b) relating to a Product Infringement shall be first applied
against payment of each Party’s cost and expense in connection therewith. Any recoveries in excess of such cost and expense shall be retained by the enforcing Party. 

(e) Licensor shall have the exclusive right to bring and control any legal action to enforce the Combination Therapy Patents against any
infringement that is not a Product Infringement, at its own expense and as it reasonably determines appropriate, and Licensor shall have the right to retain all recoveries resulting therefrom.  

ARTICLE 6 

REPRESENTATIONS AND WARRANTIES 

6.1 Mutual Representations and Warranties. Each Party hereby represents, warrants, and covenants (as applicable) to the other
Party as follows: 
 (a) Corporate Existence and Power. It is a company or corporation duly organized, validly existing, and in
good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement, including, without limitation, the right to grant the licenses granted by it hereunder. 
 (b)
Authority and Binding Agreement. As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary
corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and (iii) the Agreement has been duly executed and delivered on behalf of such Party, and
constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms. 
 (c)
No Conflict; Covenant. It is not a party to any agreement that would materially prevent it from granting the rights granted to the other Party under this Agreement or performing its obligations under the Agreement. 

(d) Compliance with Law. It shall comply in all material aspects with all applicable Laws in the course of performing its
obligations and exercising its rights under this Agreement. 
 6.2 Additional Representations and Warranties of Licensor.
Licensor represents, warrants, and covenants (as applicable) to Licensee that, as of the Effective Date: 
 (a) Licensor has the right
under the Licensed Technology and Combination Therapy Patent to grant the licenses to Licensee as purported to be granted pursuant to this 

  
 8. 

 
Agreement, and Licensor solely owns all right, title and interest in and to the Combination Therapy Patents, free and clear of all liens, claims and encumbrances; 

(b) Licensor has not granted, and will not grant during the Term, any license or other right under the Licensed Technology or
Combination Therapy Patents that is inconsistent with the license granted to Licensee hereunder; 
 (c) Exhibit B includes all
Patent Rights Controlled by Licensor as of the Effective Date that claim the Licensed T Cell Therapeutic(s); 
 (d) Licensor has not
received any written notice from any Third Party asserting or alleging that the development of any Licensed Technology or Licensed T Cell Therapeutic(s) or Combination Therapy Patent prior to the Effective Date infringed or misappropriated the
intellectual property rights of such Third Party; and 
 (e) there is no pending or, to Licensors’ knowledge, threatened in
writing, adverse action, suit, proceeding, or claim against Licensor involving the Licensed Technology or Licensed T Cell Therapeutic(s) or Combination Therapy Patents. 

6.3 Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 6, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR
IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY
INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL SUCH REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. Licensee understands that the Licensed Technology,
Licensed T Cell Therapeutic(s) and Combination Therapy Patents are the subject of ongoing research and development and Licensor cannot assure that the Licensed Technology, Licensed T Cell Therapeutic(s) and Combination Therapy Patents will be useful
or any Product can be successfully developed and commercialized using the Licensed Technology, Licensed T Cell Therapeutic(s) and Combination Therapy Patents. 

ARTICLE 7 

INDEMNIFICATION; LIMITATION OF LIABILITY 

7.1 Indemnification by Licensor. Licensor hereby agrees to defend, hold harmless and indemnify Licensee and its agents,
directors, officers and employees (the “Licensee Indemnitees”) from and against any and all liabilities, expenses and/or losses, including without limitation reasonable legal expenses and attorneys’ fees (collectively
“Losses”) in each case resulting from Third Party suits, claims, actions and demands (each, a “Third Party Claim”) arising directly or indirectly out of (a) a breach of any of Licensor’s obligations under
this Agreement, or (b) the negligence or willful misconduct of any Licensor Indemnitee. Licensor’s obligation to indemnify the Licensee Indemnitees pursuant to this Section 7.1 shall not apply to the extent that any such Losses arise
from any activities set forth in Section 7.2(a), (b) or (c), for which Licensee is obligated to indemnify Licensor Indemnitees under Section 7.2. 

  
 9. 

 7.2 Indemnification by Licensee. Licensee hereby agrees to defend, hold
harmless and indemnify Licensor and its agents, directors, officers and employees (the “Licensor Indemnitees”) from and against any and all Losses resulting from Third Party Claims arising directly or indirectly out of (a) a
breach of any of Licensee’s obligations under this Agreement; (b) the negligence or willful misconduct of Licensee Indemnitees; or (c) the research, development, manufacture or commercialization of any Product by or on behalf of
Licensee or its sublicensees. Licensee’s obligation to indemnify the Licensor Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses arise from any activities set forth in Section 7.1(a) or (b),
for which Licensor is obligated to indemnify Licensee Indemnitees under Section 7.1. 
 7.3 Procedure. The indemnified
Party shall provide the indemnifying Party with prompt notice of the claim giving rise to the indemnification obligation pursuant to this Article 7 and the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or
settle any such claim; provided, however, that the indemnifying Party shall not enter into any settlement for damages other than monetary damages without the indemnified Party’s written consent, such consent not to be unreasonably
withheld. The indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party. If the Parties cannot agree as to the
application of Sections 7.1 and 7.2 to any particular Third-Party Claim, the Parties may conduct separate defenses of such Third-Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with Sections 7.1 and 7.2
above upon resolution of the underlying claim, notwithstanding the provisions of this Section 7.3 requiring the indemnified Party to tender to the indemnifying Party the exclusive ability to defend such claim or suit. 

7.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, OR INDIRECT
DAMAGES OR LOSS OF PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 7.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT
THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 7.1 OR 7.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 8. 

7.5 Insurance. Licensee shall procure and maintain insurance, including product liability insurance if applicable, adequate to
cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated at all times. It is understood that such insurance shall not be construed to create a limit of Licensee’s
liabilities under this Agreement, including with respect to its indemnification obligations under this Article 7. Licensee shall provide Licensor with written evidence of such insurance upon request, and shall provide Licensor with written notice at
least [***] prior to the cancellation, non-renewal or material change in such insurance. 

  
 10. 

 ARTICLE 8 

CONFIDENTIALITY 

8.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties,
each Party agrees that, for the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the
exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party pursuant to this Agreement. The foregoing confidentiality and non-use obligations shall
not apply to any portion of the Confidential Information that the receiving Party can demonstrate by competent written proof: 
 (a)
was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party; 

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;

 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any
act or omission of the receiving Party in breach of this Agreement; 
 (d) is subsequently disclosed to the receiving Party by a Third
Party who has a legal right to make such disclosure; or 
 (e) is subsequently independently discovered or developed by the receiving
Party without the aid, application, or use of the disclosing Party’s Confidential Information, as evidenced by a contemporaneous writing. 

8.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 8.1, a Party may disclose the other
Party’s Confidential Information and the terms of this Agreement to the extent: 
 (a) such disclosure: (i) is reasonably
necessary for the filing or prosecuting patent rights as contemplated by this Agreement; or (ii) is reasonably necessary for the prosecuting or defending litigation as contemplated by this Agreement; or 

(b) such disclosure is reasonably necessary: (i) to such Party’s directors, attorneys, independent accountants or financial
advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to the receiving Party, provided that in each such case on the condition that such directors, attorneys, independent
accountants and financial advisors are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; or (ii) to actual or potential investors, acquirors, licensors,
licensees, collaborators or other business partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, license or collaboration; provided that in each such case on the condition that such disclosees
are bound by confidentiality and non-use obligations consistent with those contained in the Agreement; 

  
 11. 

 (c) such disclosure is required by judicial or administrative process, provided that
in such event such Party shall promptly inform the other Party such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or
administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Article 8, and the Party disclosing Confidential Information pursuant to law or court order shall
take all steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information. 

8.3 Scientific Publication. Except to the extent required by applicable Laws, Licensee shall not publish any peer-reviewed
manuscripts, or give other forms of public disclosure such as abstracts and presentations, relating to the Licensed Technology or Licensed T Cell Therapeutic(s), without Licensor’s review and approval. Licensee shall deliver to Licensor for
review and approval the draft of any proposed scientific publication or presentation relating to the Licensed Technology or Licensed T Cell Therapeutic(s) at least [***] before its intended submission for publication. [***] Licensee agrees to
acknowledge the contribution of Licensor and its employees in all scientific publication as scientifically appropriate. 
 8.4 Publicity.

 (a) Subject to the rest of this Section 8.4, no disclosure of the terms of this Agreement may be made by either Party, and
no Party shall use the name, trademark, trade name or logo of the other Party, its affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior
express written permission of the other Party, except as may be required by Law. 
 (b) A Party may disclose this Agreement and its
terms in securities filings with the Securities Exchange Commission or equivalent foreign agency (the “SEC”) to the extent required by Law after complying with the procedure set forth in this Section 8.4. In such event, the
Party seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less
than [***] after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines proscribed by applicable SEC
regulations. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of the Agreement from the SEC as represented by the redacted version reviewed by the other Party. 

(c) Each Party acknowledges that the other Party may be legally required to make public disclosures (including in filings with the SEC)
of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by Law, provided that the Party seeking such disclosure first provides the other Party a
copy of the proposed disclosure, and provided further that (except to the extent that 

  
 12. 

 
the Party seeking disclosure is required to disclose such information to comply with applicable Laws) if the other Party demonstrates to the reasonable satisfaction of the Party seeking
disclosure, within [***] of such Party’s providing the copy, that the public disclosure of previously undisclosed information will materially adversely affect the development and/or commercialization of the Licensed Technology, Licensed T Cell
Therapeutic(s) or Product, the Party seeking disclosure will remove from the disclosure such specific previously undisclosed information as the other Party shall reasonably request to be removed. 

8.5 Equitable Relief. Each Party acknowledges that a breach of this Article 8 cannot reasonably or adequately be compensated in
damages in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this
Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein. 

ARTICLE 9 
 TERM AND
TERMINATION 
 9.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated
pursuant to this Article 9, shall remain in effect until the expiration of the Licensor Patents and Combination Therapy Patents. Upon the expiration (but not earlier termination) of the Agreement, the license granted to Licensee under the Licensed
Technology shall continue and become perpetual and irrevocable. 
 9.2 Termination for Convenience. [***]

9.3 Termination for Breach. Each Party shall have the right to terminate this Agreement in its entirety immediately upon written
notice to the other Party, if the other Party materially breaches its material obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within
[***] from the date of such notice.  
 9.4 Termination for Bankruptcy. Each Party shall have the right to terminate
this Agreement in its entirety immediately upon written notice to the other Party, if the other Party shall file in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of substantially all of its assets, or if such other Party proposes a written agreement of composition or extension of substantially all of
its debts, or if such other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within [***] after the filing thereof, or if such other Party shall propose or be
a party to any dissolution or liquidation, or if 

  
 13. 

 
such other Party shall make an assignment of substantially all of its assets for the benefit of creditors. 

9.5 Termination for Patent Challenge. Except to the extent the following is unenforceable under the Laws of a particular
jurisdiction, Licensor may terminate this Agreement immediately upon written notice to Licensee, if Licensee, either by itself or in association with any other person or entity, commences any legal or administrative action or proceeding challenging
the validity, patentability, enforceability or scope of any Licensed Patents. 
 9.6 Effect of Termination. 

(a) Termination of License. Upon any termination of this Agreement for any reason, the licenses granted by Licensor to Licensee
under this Agreement shall terminate. 
 (b) Continuation of Sublicense. In the event that this Agreement is terminated by
Licensor at a time when there is a Third Party sublicensee in good standing of its sublicense agreement with Licensee, and such termination did not arise from any acts or omissions of such Third Party sublicensee, then, Licensor shall, upon such
sublicensee’s request within [***] after termination, enter into a license agreement with such Third Party sublicensee, whereby such Third Party sublicensee will receive a license directly from Licensor under the Licensed Technology and
Combination Therapy Patent as a substitute of its sublicense from Licensee. Such direct license shall on substantially the same terms and conditions as this Agreement but shall be the same scope as its sublicense from Licensee in terms of licensed
product, field, and territory. 
 (c) Return of Confidential Information. Each Party shall promptly return to the other Party
all Confidential Information of such other Party. 
 9.7 Survival. Expiration or termination of this Agreement shall not affect
the rights or obligations of the Parties under this Agreement that have accrued prior to the date of expiration or termination. Without limiting the foregoing, the following provisions shall survive any expiration or termination of this Agreement:
Sections 6.3, 9.6, 9.7 and 9.8, Articles 7, 8, 10 and 11. 
 9.8 Termination Not Sole Remedy. Termination is not the sole
remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. 

ARTICLE 10 
 DISPUTE
RESOLUTION 
 10.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during
the Term which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual
cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 10 to resolve any controversy or claim arising out of, relating to or in connection with any provision
of this Agreement, if and when a dispute arises under this Agreement. 

  
 14. 

 10.2 Internal Resolution. With respect to all disputes arising between the
Parties under this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within [***] after
such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the Chief Executive Officers of the Parties for attempted resolution by good faith negotiations within [***] after such notice is
received. 
 10.3 Binding Arbitration. If the Chief Executive Officers of the Parties are not able to resolve such disputed
matter [***] and either Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim (defined in Section 10.4 below) shall be finally resolved by binding arbitration administered by [***], and
judgment on the arbitration award may be entered in any court having jurisdiction thereof. The Parties agree that: 
 (a) The
arbitration shall be conducted by a single arbitrator jointly selected by the Parties. If the Parties are unable or fail to agree upon the arbitrator within [***] after the initiation of the arbitration, the arbitrator shall be appointed by [***].
The place of arbitration shall be [***], and all proceedings and communications shall be in English. 
 (b) Either Party may apply to
the arbitrator for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any
injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party’s
compensatory damage. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrator’s fees and any administrative fees of arbitration regardless of the outcome of such arbitration. 

(c) Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor the arbitrator may disclose the
existence, content, or results of the arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy
or claim would be barred by the applicable California statute of limitations. 
 10.4 Excluded Claim. As used in
Section 10.3, the term “Excluded Claim” shall mean any dispute, controversy or claim that concerns (a) the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or
copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. Excluded Claims shall be determined by a court of competent jurisdiction. 

ARTICLE 11 

MISCELLANEOUS 
 11.1
Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between
the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements and understandings between the Parties with respect to the subject matter hereof. There are no

  
 15. 

 
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No
subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

11.2 Force Majeure. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such
performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues, and the nonperforming
Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the reasonable control of the nonperforming Party, including without limitation, an act of God or
terrorism, involuntary compliance with any regulation, law or order of any government, war, civil commotion, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake,
storm or like catastrophe. If a force majeure persists for more than [***], then the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays caused by such force
majeure. 
 11.3 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall
specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 11.3, and shall be deemed to
have been given for all purposes (a) when received, if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b) five (5) business days after mailing, if mailed by first class certified or registered
airmail, postage prepaid, return receipt requested. 
  

			
	If to Licensor:	  	TVAX Biomedical, Inc.
		  	 Suite 700
 10900 S. Clay Blair
Blvd

		  	Olathe, Kansas 66061
		  	Attention: Wayne O. Carter, Ph.D.
		  	Fax: 913.492.2243
		
	If to Licensee:	  	V2ACT Therapeutics, LLC
		  	3030 Bunker Hill Street
		  	Suite 310
		  	San Diego, CA 92109
		  	Attention: Thomas D. Zindrick, J.D.
		  	Fax: 858.483.0026

 11.4 No Strict Construction; Headings. This Agreement has been prepared jointly and shall
not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and
Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

  
 16. 

 11.5 Assignment. Neither Party may assign or transfer this Agreement or any
rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party’s consent to an affiliate or to a successor to substantially all of the business of such
Party to which this Agreement relates (whether by merger, sale of stock, sale of assets or other transaction). Any permitted successor or assignee of rights and/or obligations hereunder shall, in writing to the other Party, expressly assume
performance of such rights and/or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 11.5 shall be
null, void and of no legal effect. 
 11.6 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

11.7 Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of
competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

11.8 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or
other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period
of time. 
 11.9 Independent Contractors. Each Party shall act solely as an independent contractor, and nothing in this
Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners
between the Parties. 
 11.10 English Language. This Agreement was prepared in the English language, which language shall
govern the interpretation of, and any dispute regarding, the terms of this Agreement. To the extent this Agreement requires a Party to provide to the other Party Information, correspondence, notice and/or other documentation, such Party shall
provide such Information, correspondence, notice and/or other documentation in the English language. 
 11.11 Governing Law.
This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of California, without giving effect to any choice of law principles that would require
the application of the laws of a different state. 
 11.12 Counterparts. This Agreement may be executed in one (1) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

{SIGNATURE PAGE FOLLOWS} 

 

  
 17. 

 IN WITNESS WHEREOF, the Parties have
executed this License Agreement in duplicate originals by their duly authorized officers as of the Effective Date. 
  

									
	TVAX Biomedical, Inc.	 		  	V2ACT Therapeutics, LLC
					
	By:	 	 /s/ Wayne O. Carter
	 		  	By:	 	 /s/ Thomas D. Zindrick

	Name:	 	Wayne O. Carter	 		  	Name:	 	Thomas D. Zindrick
	Title:	 	Chief Executive Officer	 		  	Title:	 	Manager

 List of Exhibits: 
  

			
	Exhibit A:	  	Combination Therapy Patents
	Exhibit B:	  	Licensed Patents

 EXHIBIT A 

COMBINATION THERAPY PATENTS 

[***] 

 EXHIBIT B 

LICENSED PATENTS 
 [***] 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN
OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 FIRST
AMENDMENT TO THE LICENSE AGREEMENT 
 This FIRST AMENDMENT TO THE LICENSE
AGREEMENT (the “First Amendment”) is made and entered into as of September 26, 2021 (the “First Amendment Date”) by and between: 

TVAX Biomedical, Inc., a Delaware corporation with its principal place of business at 10900 S. Clay Blair Blvd., Suite 700 Olathe, KS 66061
(“Licensor”), and 
 V2ACT Therapeutics, LLC, a Delaware limited liability company with its principal place of business at 3030 Bunker Hill
Street, Suite 310, San Diego, CA 92109 (“Licensee”). 
 Licensor and Licensee are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
 WHEREAS, Licensor and Licensee are
parties to that certain License Agreement, dated June 18, 2021 (the “Agreement”), pursuant to which Licensor granted to Licensee a non-exclusive and worldwide license to certain
intellectual properties related to cell therapy for Licensee to develop and commercialize therapeutic products that combine T-Cell therapy and therapeutic virus; and 

WHEREAS, the Parties now wish to amend the Agreement to exclude China from such license. 

NOW THEREFORE, in consideration of the mutual promises and agreement set forth herein, and for other good
and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1.
Section 1.18 is hereby replaced with the following: 
  

	 	“1.18	 “Territory” means worldwide except for China. For the purpose of this Agreement,
China includes mainland China, Hong Kong, Macau and Taiwan.” 

 2. The last sentence of Section 2.3
shall be replaced with the following: 
 “Licensee covenants that it will not, and it will not permit any of its sublicensees to, use or
practice any Licensed Technology outside the Field or outside the Territory.” 
 3. Section 2.4(a) is hereby replaced with
the following: 
 “(a) During the Term of this Agreement, neither Licensor nor any of its Affiliates (other than an Acquirer as
set forth in Section 2.4(b) below) shall, directly or indirectly, develop, commercialize, promote, make, have made, sell, offer for sale, import and/or export, or enter into 

 
any collaboration or license agreement with any Third Party in connection with the development, commercialization, promotion, manufacture, sale, offering for sale, importation and/or exportation
of, [***] in the Territory; provided that the foregoing non-compete obligation shall no longer apply if [***] or, [***] (for clarity, in such event, the license rights set forth in Sections 2.1 and 2.2
shall remain in full force and effect, and the license under Section 2.1(b) shall remain exclusive). For clarity, nothing herein shall limit or restrict Licensor’s right outside the Territory or Licensor’s right to develop,
commercialize or exploit [***].” 
 4. This First Amendment amends the terms of the Agreement as expressly provided above, and
the Agreement, as so amended and including all of its other terms and provisions that are not amended, remains in full force and effect. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement. The validity,
performance, construction, and effect of this First Amendment shall be governed by and construed under the substantive laws of the State of California, without regard to conflicts of law rules that would cause the application of the laws of another
jurisdiction. This First Amendment may be executed in counterparts, all of which taken together shall be regarded as one and the same instrument. 

IN WITNESS WHEREOF, the Parties have executed this First Amendment in
duplicate originals by their duly authorized officers as of the First Amendment Date. 
  

									
	TVAX Biomedial, Inc.	 		  	V2ACT Therapeutics, LLC
					
	By:	 	 /s/ Wayne O. Carter
	 		  	By:	  	 /s/ Thomas D. Zindrick

	Name:	 	Wayne O. Carter	 		  	Name:	  	Thomas D. Zindrick
	Title:	 	Chief Executive Officer	 		  	Title:	  	Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]